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ABSTRACT: 
 
As multiple stakeholders rush to address the opioid epidemic, federal policy definitively asserts 
Medication Assisted Treatment (MAT) constitutes the most effective solution and should be 
expanded to all persons with Opioid Use Disorder (OUD).  This article traces how federal policy 
strategically collapsed different categories of persons who misuse opioids – those with 
physiological dependence along with persons with addiction – and why discounting relevant 
differences contradicts current research.  Delving into controversial presumptions weaving 
addiction science, healthy policy, and law, this article explains the intersection between addiction 
and crime, personal choice and neurobiology, and analyzes how current evidence in fact 
demonstrates critical flaws underlying the premise of MAT.  Media reports, litigation, and case 
law exemplify the tragic outcomes of MAT’s failures when Opioid Treatment Providers offer 
insufficient care to address patients’ underlying addiction.  As a result, patients merely obtain an 
additional substance that fuels active polysubstance abuse, resulting in patient impairment 
undermining individual recovery and posing a threat to public safety and welfare. 
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INTRODUCTION 
In 2017, media began reporting on the case Commonwealth v. Eldred, in which Julie 
Eldred pled guilty to larceny for stealing jewelry to finance her habit of abusing fentanyl.1  As a 
condition of her probation, the court ordered Eldred to remain “drug free” but permitted her to 
utilize Suboxone, a partial opioid agonist, as part of medication assisted treatment (MAT) for her 
Opioid Use Disorder (OUD).2  Several days into outpatient treatment, Eldred relapsed by 
abusing fentanyl.3 Eldred violated the probation condition to remain drug free, and failed the 
court’s drug toxicology screening.4  Based on her probation violation, the court ordered Eldred 
into an inpatient facility.5  Eldred was held in jail for several days until her attorney could find 
her a space in an inpatient treatment facility.6  Eldred’s attorney and media reports portrayed the 
case as punishing people for their addiction, asserted Eldred’s relapse constituted an action she 
could not control, and called the court’s action “cruel, arbitrary, and unfair.”7  Eldred represents 
multiple assumptions underlying the current opioid crisis from how we define substance abuse 
and addiction; why substance abuse intersects with crime and involves public safety; whether 
persons with a substance use disorder (SUD) have any control over their actions; and whether the 
                                                           
1 Deborah Becker, Court to Rule on Whether Relapse by and Addicted Opioid User Should Be a Crime, NPR (Oct. 
26, 2017), https://www.npr.org/sections/health-shots/2017/10/26/559541332/court-to-rule-on-whether-relapse-by-
an-addicted-opioid-user-should-be-a-crime; Maura Ewing, ‘The Court System Shouldn’t Interrupt the Treatment 
Process,’ THE ATLANTIC (Dec. 16, 2017), https://www.theatlantic.com/politics/archive/2017/12/opioids-
massachusetts-supreme-court/548480/. 
2 See Brief for the Probationer on a Reported Question and On Appeal from Finding a Probation Violation, 
Commonwealth v. Eldred, No. SJC 12279, (Mass. June 2017) (hereinafter “Eldred Brief”); Brief of the 
Commonwealth of Massachusetts on a Reported Question and On Appeal from Finding a Probation Violation, 
Commonwealth v. Eldred, No. SJC 12279, (Mass. Aug. 2017) (hereinafter “Commonwealth Brief”). 
3 Id. 
4 Id. 
5 Id. 
6 Id.; Alanna Durkin, If Addiction is a Disease, Should Relapse Mean Jail Time?, U.S. NEWS & WORLD REPORT 
(Oct. 22, 2017), https://www.usnews.com/news/news/articles/2017-10-02/if-addiction-is-a-disease-should-relapse-
mean-jail-time. 
7 Eldred Brief, supra note 2, at 6; Becker, supra note 1; Ewing, supra note 1; Maria Kramer, SJC to Weigh if Courts 
Can Force Sobriety on Drug Users, BOSTON GLOBE (Sept. 24, 2017), 
https://www.bostonglobe.com/metro/2017/09/24/sjc-weigh-courts-can-force-sobriety-drug-
users/6a9dm1MSqufTD3I6bbuFoJ/story.html. 
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federal policy presumption that expanding access to MAT constitutes an effective and optimal 
solution for persons with OUD.8 
In Part I, this article will summarize arguments presented in Commonwealth v. Eldred, 
which mirror many of the ongoing health policy debates relating to defining SUD, and will 
describe the intersection between substance abuse, public safety, and crime.  Part II will outline 
federal policy set forth by the National Institute on Drug Abuse (NIDA) that describes SUD as a 
brain disease that “hijacks”9 normal neurobiological functioning, impairs decision-making, and 
impedes control.10  According to NIDA and the Substance Abuse and Mental Health 
Administration (SAMHSA), SUD is similar to other chronic lifelong diseases, in that it requires 
treatment using highly effective medication in place of punishment, and relapse constitutes an 
expected outcome.11  Despite the dominant model classifying SUD as a chronic brain disease, 
not all health professionals and scientists agree.  Part II of this article will also provide an 
overview of conflicting viewpoints demonstrating flaws in the current brain disease model, 
articulate why SUD is unlike other diseases, explain how a narrow neurobiological focus 
                                                           
8 See Office of the Assistant Secretary for Planning and Evaluation, Opioid Abuse In The U.S. And HHS Actions To 
Address Opioid-Drug Related Overdoses And Deaths - Executive Summary, DEPT. HEALTH AND HUMAN SERVICES 
(Mar. 26, 2015), https://aspe.hhs.gov/pdf-document/opioid-abuse-us-and-hhs-actions-address-opioid-drug-related-
overdoses-and-deaths-executive-summary.Drug; Effective Treatment for Opioid Addiction, NATIONAL INSTITUTE ON 
DRUG ABUSE, (Nov. 2016), https://www.drugabuse.gov/publications/effective-treatments-opioid-
addiction/effective-treatments-opioid-addiction (hereinafter “Effective Treatment for Opioid Addiction”);  
Medications to Treat Opioid Use Disorder, NATIONAL INSTITUTE ON DRUG ABUSE, (Mar. 2018), 
https://www.drugabuse.gov/publications/research-reports/medications-to-treat-opioid-addiction/overview 
(hereinafter “Medications to Treat Opioid Use Disorder”); FDA Takes New Steps To Advance The Development Of 
Innovative Products For Treating Opioid Use Disorder, FOOD AND DRUG ADMINISTRATION (Apr. 20, 2018), 
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm605248.html. 
9 Alan Leshner, Addiction is a Brain Disease and Why it Matters, 278 (5335) SCIENCE 45 (1997). 
10 Id.; Drug Facts: Treatment Approaches for Drug Addiction, NATIONAL INSTITUTE ON DRUG ABUSE (Jan. 2018), 
https://www.drugabuse.gov/publications/drugfacts/treatment-approaches-drug-addiction (hereinafter “Drug Facts”); 
Drugs, Brains, and Behavior: The Science of Addiction, NATIONAL INSTITUTE ON DRUG ABUSE (Jul. 2014), 
https://www.drugabuse.gov/publications/drugs-brains-behavior-science-addiction/preface (hereinafter “Drugs, 
Brain, and Behavior”). 
11 Id.  
  
4 
undermines strategies to prevent and treat SUD, and why the concept of choice and personal 
agency constitutes a vital part of recovery.  
Part III describes the evidence behind MAT, outlines three FDA approved medications 
used in MAT, and provides an overview of laws governing their use in medical care. Part IV 
provides critical analysis of the metrics health professionals use to determine MAT efficacy, 
discusses the impact of MAT on quality of life and potential recovery, and why current evidence 
does not support expanding MAT to all persons with OUD. Finally, Part V will consider the 
implications of expanding MAT by examining massive shortcomings relating to regulation of 
Opioid Treatment Providers (OTPs), discrepancies in treatment quality and regulatory 
compliance, and how case law compels a fresh examination of the current treatment paradigm. 
I. THE IMPACT OF DRUG ABUSE ON PUBLIC SAFETY AND WELFARE 
A. Commonwealth v. Eldred 
Julie Eldred began experimenting with OxyContin in high school, when occasional use to 
ease social anxiety expanded to abusing heroin and years of struggling with addiction.12  
Eldred’s larceny charge was also not her first: she had been arrested previously on another 
larceny charge, during which she also violated her probation by abusing opioids.13  The present 
case, Commonwealth v. Eldred, demonstrates the pervasive struggle with addiction, relapse, and 
the intersection of SUD and crime.14  Persons with SUD are not punished for their status of 
having an addiction, but instead for specific criminal acts that impact public welfare and safety.    
                                                           
12 Ewing, supra note 1. 
13 Id.  
14 See also Eric Westervelt, To Save Opioid Addicts, This Experimental Court is Ditching the Delays, NPR (Oct. 5, 
2017), https://www.npr.org/sections/health-shots/2017/10/05/553830794/to-save-opioid-addicts-this-experimental-
court-is-ditching-the-delays, (discussing crimes such as petty larceny as a means to obtain money to purchase drugs 
and a new model of diversion into rapid treatment). 
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Eldred raised controversial questions and attracted national attention. Multiple interested 
parties filed amicus briefs on behalf of each party attempting to distill the answers to murky 
questions in the realm of penalties, addiction, and treatment.  If SUD constitutes a brain disease 
and relapse is inevitable, then may the court impose a probation condition for Eldred to remain 
drug free (in this case, permitting prescribed Suboxone)?  Is her compulsion to continue to abuse 
illicit drugs so overwhelming that she cannot resist?  If she violated her probation by abusing 
fentanyl, may the court find she violated the conditions of her probation?  Eldred raises questions 
not only of the parameters of criminal responsibility, but also fundamental questions of choice, 
agency, and the extent of compulsion.  The resolution of this case, and how the court views 
relapse (even when receiving treatment) and a condition to remain drug free will have significant 
consequences for the ability to sanction criminal acts committed by persons with SUD to protect 
public safety.  It also raises broader questions of what constitutes effective treatment for persons 
with SUD in a manner that advances compassion and aids in successful recovery. 
Eldred’s Arguments 
In appealing the probation violation, counsel for Eldred asserted a variety of claims 
premised on the brain disease model of addiction.  Adopting former NIDA Director Alan 
Leshner’s terminology, Eldred argued drug abuse hijacked her brain, initiating a series of 
modifications to brain structure and learning that impaired her ability to control her actions.15  
Marked by an overwhelming desire to continue abusing drugs, Eldred asserted she experienced 
intolerable distress if she stopped using.16  This prompted a vicious cycle of drug seeking that 
                                                           
15 Eldred Brief, supra note 2, at 1, 8-9, 11-12, 27. 
16 Id. at 8-9. 
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overpowered her and undermined her ability to control her impulse to use fentanyl despite the 
threat of negative consequences.17   
Eldred also used NIDA’s metaphor that SUD is like other diseases, such as diabetes or 
hypertension, because these diseases have both physiological and behavioral aspects involved in 
their progression and management.18  Based on this comparison, a person with hypertension who 
experiences high blood pressure also experiences a relapse of a disease, but we view the state of 
high blood pressure as an involuntary medical condition, an inherent symptom of the disease, 
and the patient cannot control the disease symptoms.  Just as we would not punish a person with 
hypertension who experiences high blood pressure, Eldred argued relapsing and abusing fentanyl 
constitutes a symptom of SUD – a symptom that she cannot control and the court cannot 
penalize.19  Eldred further asserted that finding a relapse violated her probation constituted an 
ineffective and counterproductive threat that merely attempted to shame Eldred for a medical 
disorder that eliminated her capacity to exert any free will over her actions.20 According to 
Eldred, that amounted to criminalizing her addiction under a different name, which is “cruel, 
arbitrary, . . . unfair,” unconstitutional, and “shocks the conscience.”21 
Eldred’s articulation of the brain disease model garnered the support of multiple parties 
including the Massachusetts Medical Society and the American Civil Liberties Union of 
Massachusetts, both submitting amicus briefs echoing Eldred’s arguments.22  The Massachusetts 
Medical Society further issued a public statement on the case, urging the court to adopt Eldred’s 
                                                           
17 Id. at 1, 8-9. 
18 Id. at 11-12, 14. 
19 Id. at 11-12, 14, 33, 37. 
20 Id. at 32-33. 
21 Id. at 6, 37. 
22 Amicus Curiae Brief of the American Civil Liberties Union of Massachusetts et al., Commonwealth v. Eldred, No. 
SJC 12279, (Mass. Sept. 2017); Amicus Curiae Brief of the Massachusetts Medical Society et al., Commonwealth v. 
Eldred, No. SJC 12279, (Mass. Sept. 2017). 
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arguments proffered in the appeal.  The Massachusetts Medical Society asserted the medical 
community operates with a “clear scientific consensus” that SUD is a chronic condition, relapse 
is an “almost inevitable” symptom of the disease, and an order to refrain from abusing drugs 
during treatment as a condition of probation “condemns patients for living with a chronic 
disease.”23  The American Civil Liberties Union of Massachusetts similarly declared enforcing a 
drug free condition of probation is “dangerous and unjust.” 24 
The Commonwealth’s Arguments 
The Commonwealth’s arguments supported the court’s finding that Eldred’s decision to 
abuse fentanyl violated her probation and described pertinent nuances between SUD, choice, and 
punishable offenses.25  As a preliminary note, the Commonwealth clarified that Eldred’s 
involvement in the criminal justice system arose from her admission of guilt to a larceny 
charge.26  In lieu of incarcerating Eldred for larceny, the court offered probation and treatment 
with a condition to refrain from abusing illicit substances.  According to the Commonwealth, 
drug free conditions on probation enforced through periodic drug testing are designed to promote 
compliance and further public safety: in Eldred’s case, treatment compliance to assist in her 
recovery and reduce her potential of future involvement in the criminal justice system.27   
The Commonwealth noted that the brain disease model of addiction is not only 
controversial and contested by scientists and health professionals, but also fails to support the 
principle that persons with SUD lose their free will and are completely unable to exert control 
                                                           
23 Id.; MMS Releases Statement Regarding Amicus Brief in Commonwealth v. Eldred, MASSACHUSETTS MEDICAL 
SOCIETY (Sept.19, 2017), http://www.massmed.org/News-and-Publications/MMS-News-Releases/MMS-Releases-
Statement-Regarding-Amicus-Brief-in-Commonwealth-v--Julie-Eldred/#.WzJPxKdKg2w. 
24 Id.  
25 The Commonwealth asserted although people with SUD may face difficulties with addiction, they do not lose 
their free will to make alternate choices toward recovery.  Further, courts do not punish people for the state of 
having an addiction, but instead for specific crimes that impact public safety and welfare.  
26 Commonwealth Brief, supra note 2, at 2-3. 
27 Id. at 2, 15-16. 
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over their actions.28  The Commonwealth rejected Eldred’s assertion that SUD is similar to other 
chronic diseases because persons with SUD can and do respond positively to contingency 
management plans (giving patients tangible reinforcement for positive behaviors and sanctioning 
negative behaviors), which would have no impact on a disease such as cancer or Alzheimer’s 
disease.29  Even if drug abuse induces neurobiological changes, the Commonwealth clarified it is 
unlike other brain diseases, such as Alzheimer’s disease, where the person loses genuine capacity 
to control the disease by acts of will.30  The distinguishing feature of SUD compared to another 
diseases, such as Alzheimer’s disease or cancer, lies in Eldred’s capacity to exert control over 
her actions.   
Thus, although Eldred’s decision-making may be impaired, she is not a powerless 
automaton.31  Imposing a condition to remain drug free as part of probation can motivate 
engagement in treatment because successful recovery relies on the person’s individual 
commitment to refrain from drug abuse.32 Indeed, according to the Commonwealth, no court has 
found that drug use by a person with SUD is involuntary, because this would undermine the 
court’s ability to assign culpability for drug-related crimes.33  Most importantly, the court’s 
finding of a probation violation was not punishing Eldred for her mere status as a person with 
addiction, but for a specific act – a willful violation of probation corresponding to her criminal 
penalty for larceny.34 
 
 
                                                           
28 Id. at 5-6, 12. 
29 Id. at 7. 
30 Id. at 11. 
31 Id. at 37-38. 
32 Id. at 11, 32, 34. 
33 Id. at 36. 
34 Id. at 21, 34. 
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B. The Intersection of Drug Abuse and Crime  
 Some media and legal scholarship decries a failed war on drugs, portraying drug abuse 
and addiction as senseless incarceration of persons merely based on their addiction.35 Yet as the 
Commonwealth noted, many cases, including Eldred’s, are not punishing persons for having an 
addiction but involve a specific crime that directly impacts the welfare of society, which may be 
motivated or influenced by the individual’s drug abuse.  Illicit drugs are costly to both the 
individual and society: they decrease individual and societal productivity, increase medical costs, 
contribute to mental distress, and can result in death.36  Crimes connected to drug use include 
offenses such as distributing the drug to others, crimes related to attempting to obtain money to 
purchase drugs (such as larceny), offenses associated with a lifestyle of associating with illicit 
markets, and public safety (driving under the influence, neglect of dependents, and interpersonal 
violence).37  Political scientist James Q. Wilson aptly argued the notion that drug abuse is a 
victimless crime “is not only absurd by dangerous” because we “all have a stake in ensuring each 
of us displays minimal levels of dignity, responsibility and empathy.” 38  This translates to an 
                                                           
35 See Marc Kupanski, It’s Time to Kick Our Addiction to the War on Drugs, STAT NEWS (Apr. 25, 2017), available 
at https://www.statnews.com/2017/04/25/opioids-war-on-drugs-harm-reduction/ (asserting punishment for crimes 
relating to possession and sale of drugs do not deter such crimes, and advocates for supervised drug consumption 
sites); Don Stemen, Beyond the War on Drugs, 11 HARVARD LAW & POLICY REVIEW 375, 375-377 (2017) (calling 
the war on drugs an “utter failure” that ravaged and further marginalized impoverished communities); David 
Lebowitz, Proper Subjects for Medical Treatment? Addiction, Prison-Based Drug Treatment and the Eighth 
Amendment, 14 DEPAUL JOURNAL OF HEALTH CARE LAW 271, 273 (2012) (asserting it is “uncontroversial that 
many Americans are in prison because they are addicted to drugs”).   
36 Barbara Andraka-Christou, Improving Drug Courts through Medication-Assisted Treatment for Addiction, 23 
VIRGINIA JOURNAL OF SOCIAL POLICY & LAW 179-181 (2016); Facing Addiction in America: The Surgeon 
General’s Report on Alcohol, Drugs, and Health, Office of the Surgeon General, DEPT. HEALTH AND HUMAN 
SERVICES (2016) at 1-12, available at https://addiction.surgeongeneral.gov/ (discussing costs and consequences of 
substance abuse) (hereinafter “Surgeon General’s Report). 
37 Principles of Drug Abuse Treatment for Criminal Justice Populations - A Research-Based Guide, NATIONAL 
INSTITUTE ON DRUG ABUSE (Apr. 2014), https://www.drugabuse.gov/publications/principles-drug-abuse-treatment-
criminal-justice-populations/introduction (hereinafter “Principles of Drug Abuse Treatment for Criminal Justice 
Populations”). 
38 James Q. Wilson, Against the Legalization of Drugs, COMMENTARY MAGAZINE (Feb. 1, 1990), available at 
https://www.commentarymagazine.com/articles/against-the-legalization-of-drugs/. 
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ethical responsibility to offer care and compassion to persons with addiction while also 
maintaining the public safety and welfare. 
NIDA acknowledges the connection between drug abuse and crime is well known, and 
the Federal Bureau of Investigation using Uniform Crime Reports provides statistics for the 
intersection of drug abuse and specific categories of crimes.39  To illustrate: 30% of state 
prisoners reported they committed property theft for the reason of obtaining money to purchase 
illicit drugs, and approximately 37% of state prisoners committed the crime while under the 
influence of a drug, which may impair decision-making, decrease impulse control, and diminish 
sound judgment.40  In the context of persons with opioid addiction specifically, the media has 
covered a variety of criminal allegations, such as diversion and sale of prescribed opioid 
medications (including medications intended for MAT),41 fatal motor vehicle accidents caused 
by a driver impairment by persons receiving MAT,42 and child neglect or abuse by persons 
struggling with OUD.43 
                                                           
39 Principles of Drug Abuse Treatment for Criminal Justice Populations, supra note 37; Drug Use and Crime Facts, 
Bureau of Justice Statistics, U.S. DEPARTMENT OF JUSTICE, https://www.bjs.gov/content/dcf/duc.cfm. 
40 Id.; Mirko Bargaric & Sandeep Gopalan, A Sober Assessment of the Link Between Substance Abuse and Crime – 
Eliminating Drug and Alcohol Use from the Sentencing Calculus, 56 SANTA CLARA LAW REVIEW 243, 243-302 
(2016). 
41 Deborah Sontag, At Clinics, Tumultuous Lives and Turbulent Care, NEW YORK TIMES (Nov. 17, 2013), 
https://www.nytimes.com/2013/11/.../at-clinics-tumultuous-lives-and-turbulent-care.html; Laura Ungar, Rogue 
Doctors Exploit Loopholes to Let a Powerful Drug ‘Devastate a Community,’ COURIER JOURNAL (June 8, 2017), 
https://www.courier-journal.com/story/news/investigations/2017/06/08/rogue-doctors-hands-medicine-designed-
treat-addiction-turns-into-new-habit/98522426/; Marty Schladen, Cash-only Suboxone Clinics Fuel Fears of New 
‘Pill-Mills’, THE COLUMBUS DISPATCH (Oct. 8, 2017), http://www.dispatch.com/news/20171008/cash-only-
suboxone-clinics-fuel-fears-of-new-pill-mills/1. 
42 Andrew Kruger, Judge Allows Punitive Damages in Lawsuit Against Brainerd Methadone Clinic, DULUTH NEWS 
TRIBUNE (Sept. 24, 2014), http://www.duluthnewstribune.com/news/3846521-judge-allows-punitive-damages-
lawsuit-against-brainerd-methadone-clinic; Ella Nilsen, First of Four Parts: A Life Changer: Effects of Methadone 
Treatment Extend Beyond Users, THE KEENE SENTINEL (Nov. 7, 2014), 
http://www.sentinelsource.com/news/special_reports/methadone/first-of-four-parts-a-life-changer-effects-of-
methadone/article_386944f2-c506-5974-ab01-14a7ab629502.html; Ella Nilsen, Fourth of Four Parts: A Stage Set 
for Disaster, THE KEENE SENTINEL (Nov. 11, 2014), available at 
http://www.sentinelsource.com/news/special_reports/methadone/methadone_day_4/fourth-of-four-parts-a-stage-set-
for-disaster/article_9da5f51c-a255-5d9b-aec8-85d2aadd6a17.html. 
43 Michael Levenson, Concern Mounts on Opioid Crisis’ Toll on Children, BOSTON GLOBE (Oct. 17, 2015), 
https://www.bostonglobe.com/metro/2015/10/17/concern-mounting-about-opioid-crisis-toll-
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Criminal law scholars Mirko Bagaric and Sandeep Gopalan acknowledge that many 
persons with an addiction likely do not consciously choose a life of despair and may not weigh 
the impact of their actions (such as theft, impaired driving, or child neglect).44  People born into a 
life of social disadvantage, poverty, or unspeakable emotional and physical trauma expertly 
chronicled by physician Dr. Gabor Mate may be more likely to engage in drug abuse and suffer 
from addiction.45 But Bagaric and Gopalan assert that even if negative life events predispose 
certain possibilities, this does not foreclose individual choice of alternatives.46  Importantly, the 
damage caused by these crimes, and the consequences of drug abuse, reverberate significant 
harm to surrounding persons in society which is not diminished simply because the person 
committing the crime was impaired by the influence of drugs.47   
Legal scholar and former prosecutor Susan Broderick notes the intersection of crime and 
addiction requires policymakers to consider both public health and public safety considerations 
when determining appropriate policy measures relating to SUD.48  The law, according to 
Broderick, serves as leverage to hold people accountable for their actions.49  When addiction 
                                                           
children/bbKXGdk4iKry1l6vAcb4hO/story.html; Whitney Wetzel, Surge in Child Abuse and Neglect Cases, WCHS 
EYEWITNESS NEWS, http://wchstv.com/features/eyewitness-news-i-team-investigations/surge-in-child-abuse-neglect-
cases-as-opioid-epidemic-worsens; see also Troy Quast et al., Opioid Prescription Rates and Child Removals, 37(1) 
HEALTH AFFAIRS (2017) https://doi.org/10.1377/hlthaff.2017.1023 (finding a correlation between increased opioid 
prescribing and an increase in child removal by the Florida Department of Child and Family Services due to neglect 
or abuse.) 
44 Bargaric & Gopalan, supra note 40, at 244, 264. 
45 See generally Gabor Mate, In the Realm of Hungry Ghosts (2008).  Mate chronicles his patients’ life histories and 
stories of addiction, asserting “drug addiction is a matter of brain chemistry gone askew under the influence of a 
substance and, as we will see, even before the use of mind-altering substances begins…people’s brain physiology 
doesn’t develop separately from their life events and emotions.” Mate at 30.  Mate describes neglect and severe 
physical and sexual abuse of his patients, many of who are intractable polysubstance abusers, homeless, 
unemployed, and are cycles in and out of the criminal justice system.  Many began using drugs as “emotional 
anesthetic” and “antidote” to the pain and trauma of their lives. Mate at 33. 
46 Bargaric & Gopalan, supra note 40, at 288-289.  See generally Cart Hart, High Price: A Neuroscientist’s Journal 
of Self-Discovery (2013) (describing lack of options for persons in economically and socially disadvantaged areas 
and rational choice to abuse drugs). 
47 Bargaric & Gopalan, supra note 40, at 244. 
48 See Susan Broderick, The Law and the Criminal Justice System, RECOVERY RESEARCH INSTITUTE (June 26, 
2017), https://www.recoveryanswers.org/blog/recovery-answers-from-an-criminal-justice-public-policy-expert/. 
49 Id. 
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intersects with crime, this may take the form of several options, such as drug courts that refer 
offenders with true addiction to appropriate and effective treatment. 50 This raises pertinent 
questions of how to determine whether a person needs treatment, and whether certain types of 
treatment promoted by NIDA and the Office of National Drug Control Policy, such as MAT, are 
supported by adequate evidence.51  Finally, not all drug-related offenders require treatment, and 
for offenders who may not have an addiction, providing an alternate model that uses the lever of 
the law to encourage responsible behavioral choices should be explored.52  As a model, Hawaii’s 
Opportunity Probation with Enforcement (HOPE) program employs swift, certain, and fair 
sanctions to motivate behavioral outcomes. 53  The HOPE program has demonstrated measurable 
statistical success and has been implemented in forty jurisdictions across eight states showing 
reduction in crime.54     
II. CRITICAL ANALYSIS OF THE BRAIN DISEASE MODEL  
Considering solutions to address substance abuse and finding answers to the controversial 
questions raised in Commonwealth v. Eldred requires examining the state of substance abuse in 
the United States and how federal policy defines and characterizes persons with SUD.  This 
                                                           
50 See Treatment Courts Work, NATIONAL ASSOCIATION OF DRUG COURT PROFESSIONALS, 
https://www.nadcp.org/treatment-courts-work/; Paul Larkin, Swift, Certain and Fair Punishment: 24/7 Sobriety and 
HOPE: Creative Approaches to Alcohol and Illicit-Drug Using Offenders, 105 JOURNAL OF CRIMINAL LAW & 
CRIMINOLOGY 39, 79-80 (2015) (discussing how participation in drug treatment can substantially reduce drug use 
and crime). 
51 Michael Botticelli, Memorandum: Changing Federal Terminology Regarding Substance Use and Substance Use 
Disorders, OFFICE OF NATIONAL DRUG CONTROL POLICY (Jan. 9, 2017), 
https://www.whitehouse.gov/sites/whitehouse.gov/files/images/Memo%20-
%20Changing%20Federal%20Terminology%20Regrading%20Substance%20Use%20and%20Substance%20Use%2
0Disorders.pdf (hereinafter “ONDCP Memo”). 
52 Larkin, supra note 50, at 75. 
53 Id.  Larkin provides an overview of the shortcomings used in traditional substance abuse testing, outlines the 
model for probation with frequent substance testing back by the possibility of flash incarceration for noncompliance.  
Larkin at 66-67, 71-72.  Statistics from HOPE are promising, demonstrating the program had an 80% decrease in 
positive drug tests among participants, participants were 52% less likely to be arrested for a new crime, and 72% 
less likely to use drugs.  Larkin at 73.  See also Beau Kilmer et al., Back in the National Spotlight: An Assessment of 
Recent Changes in Drug Use and Drug Policies in the United States, BROOKINGS INSTITUTE (Aug. 2016) at 16, 
https://www.brookings.edu/wp-content/uploads/2016/07/Kilmer-United-States-final-2.pdf. 
54 Kilmer, supra note 53, at 16. 
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section will provide an outline of the dominant brain disease model of addiction in federal policy 
set forth by NIDA that characterizes SUD as a chronic and relapsing medical disorder marked by 
fundamental changes in neurological functioning.  It will next provide critical analysis of the 
dominant brain disease model based on evidence showing why SUD is unlike a chronic disease, 
how neurological changes do not preclude choice, and discuss the importance of recognizing 
individual agency in recovery.  Lastly, this section will explain the significance of recognizing 
distinct populations of persons with OUD ranging from physiological dependence to addiction.    
A. The Impact of Drug Addiction and the Brain Disease Analogy 
SUD related to opioids affects a significant portion of the population in the United States: 
in 2016, 2.1 million persons had an opioid use disorder.55  U.S. annual spending on drugs has 
remained relatively stable, but the compositions of drugs of abuse has shifted, where more 
persons are abusing opioids (both prescription opioids and heroin) and marijuana.56 The Centers 
for Disease Control and Prevention has called opioid abuse a fast moving epidemic, and in 2017 
the Secretary of Health and Human Services declared the opioid crisis a public health 
emergency.57  These trends closely follow political and prescribing changes: as more physicians 
began writing more prescriptions for opioids, rates of overdose and death also skyrocketed.58  
From 1999 to 2013, the rate of overdose from OxyContin increased five-fold.59   
                                                           
55 Medications to Treat Opioid Use Disorder, supra note 8, at 3. 
56 See Kilmer, supra note 53, at 4-9. 
57 Rose Rudd et al., Increases in Drug and Opioid Overdose Deaths — United States, 2000–2014, 64(50) 
MORBIDITY AND MORTALITY WEEKLY 1378 (Jan. 1, 2016); HHS Acting Secretary Declares Public Health 
Emergency to Address National Opioid Crisis, DEPT. HEALTH AND HUMAN SERVICES (Oct. 26, 2017), 
https://www.hhs.gov/about/news/2017/10/26/hhs-acting-secretary-declares-public-health-emergency-address-
national-opioid-crisis.html. 
58 Andrew Kolodny, The Opioid Epidemic: How Marketing and Regulatory Failure Led to a Public Health Crisis, 
PHYSICIANS FOR RESPONSIBLE OPIOID PRESCRIBING, http://www.pharmedout.org/pdf/R3DSlides/Kolodny.pdf 
(hereinafter “Kolodny”); Andrew Kolodny et al., The Prescription Opioid and Heroin Crisis: a Public Health 
Approach to an Epidemic of Addiction, 36 ANNUAL REVIEW OF PUBLIC HEALTH 559 (2015) (describing the link 
between the increase in prescriptions for opioids and rising rates of overdose). 
59 Kilmer et. al., supra note 53, at 9. 
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The “Hijacked Brain”: Neurological Changes and Choice 
NIDA defines drug addiction as “compulsive, or uncontrollable, drug seeking use despite 
harmful consequences and changes in the brain, which can be long lasting.”60  People may 
initially abuse drugs for a variety of reasons, classified broadly as seeking euphoria or relief from 
dysphoria,61 including as a remedy to address “psychic pain, existential maladies, emptiness, lack 
of purpose, or isolation.”62 Although initial drug use begins as a voluntary action, as a person 
continues using the drug, it creates neurological changes in how the brain learns, remembers, and 
functions.63  Use of the drugs releases dopamine in the brain, which reinforces the pleasurable 
effects of the drug as a reward with each subsequent use.64  Repetition of these patterns induces 
neuroplastic changes in the brain, strengthening the association between the drug and euphoria, 
reinforcing the drug as a habit, and bolstering the expectation of pleasure.65 Positron emission 
tomography (PET) scans show progressive changes in areas of the brain such as the prefrontal 
cortex that affect judgment, self-control, and decision-making and gradual loss of gray matter in 
the brain.66   
                                                           
60 Drug Facts, supra note 10; see also Nora Volkow & Ting Kai Li, Drug Addiction: The Neurobiology of Addiction 
Gone Awry, 5 NATURE REVIEWS NEUROSCIENCE 963 (2004). 
61 The Definition of Addiction, AMERICAN SOCIETY OF ADDICTION MEDICINE (Apr. 12, 2011), 
https://www.asam.org/docs/default-source/public-policy-statements/1definition_of_addiction_long_4-
11.pdf?sfvrsn=a8f64512_4. 
62 Sally Satel & Scott Lilienfeld, Calling it a ‘Brain Disease’ Makes Addiction Harder to Treat, BOSTON GLOBE 
(June 22, 2017), https://www.bostonglobe.com/ideas/2017/06/22/calling-brain-disease-makes-addiction-harder-
treat/ehaJs5ZYIXpPottG89KOGK/story.html. 
63 The Science of Drug Abuse and Addiction, NATIONAL INSTITUTE ON DRUG ABUSE, 
https://www.drugabuse.gov/publications/media-guide/science-drug-abuse-addiction-basics. 
64 Id.; Neuroscience of Psychoactive Substance Use and Dependence, WORLD HEALTH ORGANIZATION (2004) at 58-
59, http://www.who.int/substance_abuse/publications/en/Neuroscience.pdf (hereinafter “WORLD HEALTH 
ORGANIZATION”); see also Rita Goldstein & Nora Volkow, Dysfunction of the Prefrontal Cortex in Addiction: 
Neuroimaging Findings and Clinical Implications, 12 NATURE REVIEWS NEUROSCIENCE 652 (2011). 
65 Nora Volkow & Marisela Morales, The Brain on Drugs: From Reward to Addiction, 162 CELL 712 at 712, 715 
(2015); see also Neuroscience of Psychoactive Substance Use and Dependence, WORLD HEALTH ORGANIZATION 
(2004), http://www.who.int/substance_abuse/publications/en/Neuroscience.pdf at 58-59 (discussing the repeated 
association between drug and reward, reinforcing effects of drug abuse, and biobehavioral learning processes). 
66 Drugs, Brains, and Behavior, supra note 10.  
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These neurological changes, according to NIDA Director Nora Volkow, impair neural 
scaffolding that enable self-control, undermining the person’s ability to resist abusing drugs.67  
Psychiatrist, Colm Connolly and colleagues demonstrated duration of substance abuse correlates 
with decreases in gray matter in the brain in areas associated with executive functioning, 
judgment, decision-making and reward processing.68  The longer a person abuses substances, the 
greater the negative impact to both neurological structure and functioning.69 Persons with SUD 
experience both altered sensitivity to negative reinforcers (consequences of their addiction, such 
as economic loss, criminal involvement, loss of child custody etc.) and also attribute excessive 
salience to the drug itself.70   Behaviors relating to drug seeking and consumption become main 
motivational drivers at the expense of other activities and responsibilities present in daily life.71   
These adaptations are what compromises a person’s ability to choose, resulting in 
compulsive drug use, which invokes Leshner’s concept of the “hijacked brain.”72  According to 
the American Society of Addiction Medicine, after continued drug abuse, a person develops a 
tolerance to the drug and “needs” the drug not to experience euphoria, but to avoid feeling the 
distress of withdrawal and associated dysphoria.73  The American Society of Addiction Medicine 
asserts, without continuing to abuse the drug of choice, the individual feels “flat, lifeless, and 
depressed.”74  
                                                           
67 Ruben Baler & Nora Volkow, Drug Addiction: The Neurobiology of Disrupted Self-Control, 12(12) TRENDS IN 
MOLECULAR MEDICINE 559 at 559, 562 (2006). 
68 Colm Connolly et al., Dissociated Gray Matter Changes With Prolonged Addiction and Extended Abstinence in 
Cocaine Users, 8(3) PLOS ONE 1 (2013) e59645. 
69 Id. at 3. 
70 Goldstein & Volkow, supra note 64, at 652. 
71 Id. 
72 Leshner originally coined the metaphor that drug abuse “hijacks” normal neurobiological functioning.  See 
Leshner, supra note 9; see also World Health Organization, supra note 64. 
73 American Society of Addiction Medicine, supra note 61; see also Drugs, Brains, and Behavior, supra note 10, at 
18 (stating a person with SUD “needs” to keep abusing drugs to try to bring dopamine functioning back to normal). 
74 American Society of Addiction Medicine, supra note 61. 
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A Diseased Brain: Addiction is Similar to Other Chronic and Relapsing Diseases 
Federal policy maintains substance abuse should be treated as a medical condition and is 
similar to other chronic diseases such as heart disease or diabetes.75  Indeed, NIDA compares 
temporal neurological modifications for persons with addiction visually represented by PET 
scans (a “diseased brain”) to images of a patient with heart disease (a “diseased heart”).76  
Extending these comparisons, federal policy set forth by NIDA,77 the Surgeon General,78 and the 
President’s Commission on Combatting Addiction and the Opioid Crisis79 classifies SUD as 
chronic and relapsing disease.  Viewing SUD as a chronic disease, relapse is not only possible, 
but likely and may be triggered by exposure to environmental cues or reminders of the drug.80  
Volkow asserts relapse does not indicate a failure of treatment, but an indication that the person 
requires an adjustment in treatment or needs treatment reinstated.81  Classifying SUD as a 
chronic neurological disease means persons with addiction will require long-term, repeated, and 
even life-long treatment.82 Only about 10% of persons with SUD receive treatment, which the 
Surgeon General identifies as a substantial treatment gap, calling for expanded access to 
treatment.83  Treatment should address not only substance abuse, but additional co-morbid 
disorders: approximately forty-one percent of persons with SUD also present with a co-occurring 
                                                           
75 Surgeon General’s Report, supra note 36, at i; Baler & Volkow, supra note 67, at 563. 
76 Drugs, Brains, and Behavior, supra note 9, at 5. 
77 Id. 
78 Surgeon General’s Report, supra note 36, at i, iv, 6, 18.  
79 Chris Christie et al., The President’s Commission on Combatting Drug Addiction and the Opioid Crisis, 
EXECUTIVE OFFICE OF THE PRESIDENT (Nov. 1, 2017) at 7, 15, 
https://www.whitehouse.gov/sites/whitehouse.gov/files/images/Final_Report_Draft_11-1-2017.pdf. 
80 Drugs, Brains, and Behavior, supra note 10, at 20, 26; Baler & Volkow, supra note 67, at 563. 
81 Drugs, Brains, and Behavior, supra note 10, at 26; Baler & Volkow, supra note 67, at 563. 
82 Baler & Volkow, supra note 67, at 563; see also Drug Facts, supra note 9. 
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mental health conditions such as depression, anxiety, or ADHD, which requires additional 
strategies for successful treatment.84  
B. Re-Examining the Brain Disease Model 
Despite NIDA’s characterization of substance abuse as a chronic and relapsing brain 
disease that fundamentally impairs individual choice, not all addiction scientists concur.  In 
Commonwealth v. Eldred, Assistant Attorney General Maria Granik compiled materials from 
neuroscientists, psychologists and psychiatrists specializing in addiction that highlight flaws in 
the brain disease model, which impacts not only future legal precedent but addiction medicine 
and public health approaches to addiction.  The Commonwealth’s brief and a supporting amicus 
brief note central assumptions within the brain disease model – that SUD is similar to other 
chronic diseases, persons with addiction experience dramatic neurological changes that 
undermine their ability to resist the compulsion from abusing drugs is not universally shared 
among experts.85  Psychologist Gene Heyman notes how we define addiction is critical for 
devising strategies to reduce its harm through effective health policy, which should include 
recognizing the role of personal agency and empowerment for recovery.86 
Addiction is Distinct from Chronic Diseases 
Classifying addiction as a brain disease began as a noble strategy to extricate persons 
with addiction from punitive moral judgment, expand research funding while legitimizing 
addiction research, and allocate treatment coverage from insurance.87   Yet the current model 
                                                           
84 Surgeon General’s Report, supra note 36, at 2-22. 
85 Commonwealth Brief, supra note 2, at 8, 12, 18 (the brain disease model is “subject to vigorous debate in the 
scientific community.”) 
86 Gene Heyman, Do Addicts Have Free Will? An Empirical Approach to a Vexing Questions, 5 ADDICTIVE 
BEHAVIOR REPORTS 85, 86 (2017). 
87 Anke Snoek, How to Recover from a Brain Disease: Is Addiction a Disease, or Is There A Disease-like Stage in 
Addiction?, 10 NEUROETHICS 185, 186 (2017); Sally Satel & Scott Lilienfeld, Addiction and the Brain-Disease 
Fallacy, 4 FRONTIERS IN PSYCHIATRY 1, 4 (2014); Satel & Lilienfeld, supra note 62; Amicus Curiae Brief of Eleven 
Addiction Experts, Commonwealth v. Eldred, No. SJC 12279, (Mass. Sept. 2017) at 7-9. 
  
18 
asserting addiction can be classified as a chronic relapsing disease similar to other diseases 
presents a variety of detrimental constraints when considering precipitating factors of addiction 
and the most appropriate methods of treatment.  Psychologist and legal scholar Stephen Morse 
notes unlike other chronic diseases such as cancer, hypertension, or diabetes, the primary 
criterion for the addiction is behavioral.88  Addiction scientists note a person with other diseases 
such as cancer cannot suppress the signs (“I will not have cancer today”), or a person with a 
brain disease such as Alzheimer’s disease cannot will one’s self to remember on call.89  Unlike a 
person struggling to manage cancer or Alzheimer’s disease, no amount of reward or punishment 
can alter the course of their disease.90   
Proponents of the brain disease model are correct in asserting many chronic diseases 
involve individual choice in the progression of the disease (e.g. diet, exercise, stress management 
for some conditions).91  Yet pharmacological strategies alone are insufficient to address any 
conditions that may have a behavior component whether addiction, hypertension or diabetes, 
because they downplay the impact of social and psychological factors driving maladaptive or 
destructive behavior. Narrow medical models of treating chronic disease are expensive, largely 
ineffective, and constitute a poor model of effective medical intervention. 92  Truly successful 
                                                           
88 Stephen Morse, Addiction Choice and Criminal Law, ADDICTION & CHOICE: RETHINKING THE RELATIONSHIP 
(Oxford University Press, 2016). 
89 Id. at 428 (asserting persons with addiction act intentionally to satisfy their desire to seek and use drugs and this is 
not an involuntary action); Id. at 432 (discussing addiction is not involuntary in the sense that a muscle reflex is 
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91 CNR’S FOR DISEASE CONTROL & PREVENTION, Chronic Disease Overview, 
https://www.cdc.gov/chronicdisease/overview/index.htm. 
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interventions for many chronic conditions – along with addiction  –  also require a new 
framework, such as the pioneering field of functional medicine that examines how to best 
intervene to prevent and reverse disease by looking at correlations between choice and 
empowering the public with strategies to take control of their health.93 Independent of how we 
classify addiction, effective health policy should examine whether the dominant model 
sufficiently addresses the complexities involved in conditions with a behavioral component. 
Addressing the behavioral component in addiction presents a distinct challenge because 
abuse of illicit substances, unlike chronic diseases, presents a substantial health and safety hazard 
not only to the person with SUD, but the general public.94 A decision to repeatedly indulge in 
doughnuts and a disdain for exercise may impact the progression of diabetes, but unlike a person 
abusing illicit substances, it does not correlate to crimes affecting public safety and welfare such 
as larceny, motor vehicle impairment, or child neglect and abuse.  When a person’s behaviors 
and choices directly impact public safety and welfare, then it is appropriate for social norms to 
reproach actions that are reckless or harmful toward others.95  In instances such as 
Commonwealth v. Eldred, when persons with SUD like Julie Eldred commit a crime, the law 
(including drug-free conditions of probation) can be an effective tool for motivating people to 
remain committed to stop using illicit substances and or engage in treatment.96  Yet this is only 
                                                           
between physical health and mental well-being which impacts co-morbid mental health conditions that often occur 
with substance abuse). 
93 Id.  
94 Commonwealth Brief, supra note 2, at 26. 
95 Satel & Lilienfeld, supra note 87, at 8; see also Kilmer, supra note 53, at 17 (stating that individuals’ actions 
threaten public health and safety it may be in society’s interest to reduce their consumption of illicit substances).  
96 Not all people who abuse substances suffer from addiction, and some may benefit from probation with a condition 
to remain drug free that utilizes swift, certain, and fair sanctions.  Other people who abuse substances and suffer 
from addiction may benefit from evidence-based treatment.  See Larkin, supra note 50, at 71-73 (discussing the 
model of swift, certain, and fair sanctions), at 75 (discussing how some offenders in the criminal justice system may 
not require treatment but would respond to probation with a system of accountability through frequent drug 
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the first part of the inquiry because compassion for persons suffering from addiction also 
requires examining whether the current model to explain addiction captures its complexities, and 
whether treatment interventions recommended in federal policy demonstrate successful 
outcomes.   
A Neurocentric View Minimizes the Importance Of Psychological And Social Factors 
Precipitating Addiction 
Psychiatrist Dr. Sally Satel and psychologist Scott Lilienfeld refer to the brain disease 
model as “dogma,” and it constitutes the foundational message from NIDA and forms the basis 
of medical school education and addiction counselor training.97  According to Satel and 
Lilienfeld, the brain disease model has dominated the field based on the assumption that if 
scientists can identify biological roots, then a person has a disease.98  Critics of the brain disease 
model argue that designating the brain as the seat of addiction is “rooted in the dubious 
assumption that neurobiology is destiny”99 and the neurocentric view of addiction 
problematically downplays psychological and social factors that contribute to addiction.100  
Though NIDA acknowledges stress constitutes a risk factor for substance abuse,101 focusing on 
neurobiology ignores people’s reasons for abusing drugs, such as scare opportunity for 
educational and economic growth,102 pessimism, a culture that normalizes drug use, emptiness, 
isolation, or lack of purpose.103  Indeed, the World Health Organization cautions that medical 
                                                           
97 Satel & Lilienfeld, supra note 87. 
98 Id. 
99 Satel & Lilienfeld, supra note 62. 
100 Satel & Lilienfield, supra note 87, at 5. 
101 Common Co-Morbidities with Substance Use Disorders, NATIONAL INSTITUTE ON DRUG ABUSE, 
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models of substance abuse may not be a wholly positive development if it oversimplifies the role 
of social policy in addressing risk factors of addiction.104  In the case of Opioid Use Disorder, 
focusing on circumstance and reason for use may also uncover a distinct category of persons 
with physiological dependence rather than addiction.  Reducing addiction to a neurobiological 
flaw directly informs the basis for the dominant treatment model, which focuses on and searches 
for a pharmacological cure.105   
Not all persons who initially use drugs develop an addiction, and both animal and human 
studies demonstrate situational factors exert substantial impact.106  Based on both animal and 
human models, Volkow and Morales estimate about 10% of persons exposed to a drug will 
develop an addiction.107  Drug abuse may be precipitated by abuse, social isolation, or extreme 
stress, which may remit with the removal or alternate management of those stressors.  One of the 
most frequently cited examples is the case of opiate addiction among U.S. Army personnel 
during the Vietnam War.  Critics of the brain disease model note that during the Vietnam War, 
10-25% of U.S. Army enlisted personnel were addicted to opium or heroin.108  To board the 
plane and return from Vietnam, the U.S. Army required personnel to demonstrate a negative 
urine screen.109  The majority of personnel passed the screen and boarded to return home on the 
first or second try.110   According to follow up studies by sociologist Lee Robbins, only 5% of 
those who displayed addiction while in Vietnam relapsed within 10 months, and 12% relapsed 
                                                           
104 WORLD HEALTH ORGANIZATION, supra note 64, at 231. 
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within 3 years.111  This example illustrates the principle that addiction may be tied to situation, 
circumstance, and context.   
In addition to situational stressors, addiction scientists posits that addiction correlates to 
developmental time frames relating to age and coping mechanisms.112  Adolescents are more 
likely to try illicit substances,113 and both neuroscientist Marc Lewis and psychologist Gene 
Heyman suggest substances initially provide an attractive balm to life’s obstacles or internal 
conflicts by providing pleasure and relief.114  This may constitute a self-destructive or 
maladaptive strategy for addressing stressful circumstances or pressures that initially appears 
appealing in the short term.115  The difficulty, according to Satel and Lilienfeld, is that most 
people would not express wish for the self-destruction that accompanies addiction: no one 
“chooses” to become a person with drug addiction.116  Yet people do make a series of 
incremental choices leading to a habit117 that grows into an undesirable outcome of having an 
addiction.118   
Neurological Changes Do Not Preclude Choice and Change 
The trajectory of drug abuse does modify neurological structure and function, but 
disagreement exists in the scientific community of how to characterize the significance of these 
differences.  Some addiction scientists posit that the modifications in neurological structure and 
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function arise in response to choice behavior and habit formation.119  The initial decision to 
abuse substances constitutes a narrow impulsive choice that focuses on immediate reward, 
referred to as delay discounting (immediate rewards of pleasure and relief take precedence over 
long term goals and considerations).120  Every subsequent decision to use the drug strengthens 
the synaptic connections of impulsivity and the compulsion to continue using the drug.121  This 
reinforces short-term gratification over long-term global consequences that include legal 
concerns, familial consequences, economic pressure, or a desire for respect.122 
Even if subsequent decisions impact neural circuitry (or even impairs individual choice), 
some addiction scientists distinguish this does not negate individual agency.  Satel and Lilienfeld 
acknowledge that SUD may constrain or impair a person’s capacity for choice, but it does not 
destroy it.123  This distinction is critical: in Commonwealth v. Eldred, Eldred’s arguments rested 
on the assertion that her SUD as scientific fact precluded her ability to refrain from substance 
abuse – that is, she could not control her subsequent relapse with fentanyl despite the court’s 
order to refrain from abusing illicit drugs while in treatment on probation for larceny. Some 
addiction scientists convincingly demonstrate that persons with SUD do retain free will, can 
reflect on multiple conflicting allegiances, and engage in self-reflection.124   
Addiction science set forth in publications by NIDA and the World Health Organization 
recognizes that contingency management (giving patients tangible rewards to reinforce positive 
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behaviors such as abstinence) are highly effective.125  In the alternative, the threat of negative 
consequences such as professional sanction or legal repercussions can also motivate individual 
choices.126 Heyman posits that persons with addiction reach a threshold of mounting 
consequences and encounter psychological changes which include reflecting on identity, familial 
role, legal concerns, and economic constraints that make heavy drug use no longer bearable.127  
Not all Persons with Addiction Require Treatment 
Addiction scientists have found rates of remission are strongly influenced by multiple 
external factors, most persons with SUD quit on their own without treatment, and SUD for most 
people is not chronic and relapsing.128  Persons who are married, more highly educated, or 
concerned about negative legal repercussions are more likely to enter remission from substance 
abuse.129  Rates of remission also correlate with external factors such as legal penalty, substance 
availability, and ethical concerns.130  To illustrate, according to historians the Harrison Narcotics 
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Tax Act reduced opiate use and addiction by as much as 50% on the population level, 
demonstrating the impact of legal availability and price.131  Availability also subjectively 
influences craving: in one study, subjects with heroin addiction who knew they could obtain the 
drug reported higher levels of craving than subjects who did not have access to heroin.132 
According to the National Epidemiologic Survey on Alcohol and Related Conditions, drug 
availability also impacts both the length of addiction and the likelihood of remission from 
substance abuse.133  Persons who have an addiction to licit substances, such as alcohol or 
tobacco, demonstrate longer periods of substance abuse and are less likely to stop using the 
substance.134  Each of these suggests persons with addiction make evaluations based on legality, 
availability, access, and price which also strongly influences rates of remission. 
Most people with an addiction stop on their own without treatment by the age of thirty135 
and addiction scientists note that entering remission constitutes the rule rather than the 
exception.136  Annually, the proportion of persons with addiction remit on their own without 
intervention and rates of asymptomatic recovery exceed 90%.137 Rates of recovery remain 
constant over time regardless of the time a person has engaged in substance abuse, which 
supports the hypothesis that a lengthy period of addiction does not necessarily constitute a barrier 
to remission.  For most people, addiction is not chronic, and most persons with addiction do not 
relapse.138  However, within the population subset that seeks treatment, the rates of relapse 
remains high which skews subsequent studies examining remission, recovery, and relapse 
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134 Id.; Heyman, supra note 112, at 49. 
135 Heyman, supra note 112, at 1-2. 
136 Satel & Lilienfeld, supra note 87, at 4. 
137  Heyman, supra note 86, at 87; Peele, supra note 128, at 98. 
138 Heyman, supra note 112, at 51. 
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rates.139   The small subset of the this population with SUD often presents with additional 
confounding issues, such as psychological co-morbid conditions, demographic differences, and 
legal concerns.140  Addiction scientists note that the population seeking treatment often 
represents the sickest subset with people, and cautions that health policy decisions that generalize 
this population are neither reflective nor accurate of the population of persons with SUD as a 
whole.141  
Careful assessment of these nuances should guide significant modifications in public 
health approaches pertaining to treatment.  If available research shows most persons with SUD 
remit on their own without treatment, then treatment should not be mandated (for example, in the 
criminal justice system) but rather offered to persons based on a tailored assessment of their 
needs and how much and what type of treatment would be most appropriate.  
The Role of Neuroplasticity in Recovery 
Research on recovery and remission also demonstrates neuroplastic modifications 
(changes in brain structure and function) from substance abuse in most instances are not 
permanent.142  Instead, current scientific research shows persons with addiction can not only 
make alternative choices143 and relearn mechanisms to respond to triggers of drug use, but 
recovery creates novel neurological changes in the brain.144   
                                                           
139 Heyman discusses one sample from military personnel with addiction during the Vietnam War.  In that sample, in 
Group 1 6% of persons sought treatment, and 70% of Group 1 relapsed.  In Group 2, 94% did not seek treatment.  
Less than 12% of Group 2 relapsed.  See Heyman, supra note 112, at 42-43. 
140 See generally Heyman, supra note 112. 
141 Satel & Lilienfeld, supra note 87, at 4. 
142 Fenton & Wiers, supra note 117, at 157 (asserting only a small subset of rare cases have enduring neurological 
damage from severe long term addiction). 
143 Satel & Lilienfeld note people with addiction can and do identify triggers and practice self-binding (making 
choices to avoid triggers such as locations, other persons with addiction, etc.) to manage cravings and can learn to 
identify the reason for using substances as a method for self-soothing.  See Satel & Lilienfeld, supra note 87, at 5. 
144 Id.  But see Fenton & Wiers, supra note 117, at 157-158 (Fenton & Wiers describe neuroplasticity and new 
cognitive abilities, and the rare cares of what they term “black swans,” or persons who have suffered severe brain 
damage from excessive and lengthy periods of drug abuse.  Most persons with addiction according to Fenton & 
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Within the brain disease model, NIDA asserts substance abuse fundamentally modifies 
the brain’s structure and function.145  Yet the same principles of conditioned learning (repetitive 
behaviors, association with reward, and  new pathways in the brain) means therapies that target 
biobehavioral learning processes also produce and correspond to neuroplastic modifications.146  
Current research demonstrates abstinence from substance abuse starts to produce changes in the 
brain within a month.147  Continued abstinence does not merely restore gray matter volume, but 
in clinical human research it increased gray matter volume beyond the control comparison.148  
Connolly and colleagues explain that abstinence requires reassertion of cognitive control and 
behavioral monitoring that was diminished during substance abuse.149  Elevated volume of gray 
matter in these areas of the brain, according to Connolly and colleagues suggest that the brain is 
not only capable of compensating in response to new demands such as maintaining abstinence, 
but gray matter development in new areas suggests recovery constitutes more than merely 
reversing gray matter loss and damage: people can guide their brains to learn and grow new 
pathways.150  
Self-Efficacy is a Crucial Component to Recovery 
 Classifying SUD as a chronic and relapsing brain disease potentially hinders recovery 
because it fails to account for each person’s ability to exert control over his or her own life.151  
                                                           
Wiers reflect some type of neurological modifications that can be unlearned and modified, and cases of severe true 
“brain disease” are rare).   
145 Drugs, Brains, and Behavior, supra note 10, at 5. 
146 WORLD HEALTH ORGANIZATION, supra note 64, at 59-60; Lewis, supra note 108, at 89-91 (discussing how a 
period of self-reflection can induce changes in the brain to permit new connections), at 131(discussing the loss of 
gray matter in the brain), at (137-138 (discussing how recovery not merely returns the brain to a pre-addiction state, 
but changes in the brain from extended periods of recovery correspond to new areas of growth)). 
147 Xuyi Wang et al., Changes In Brain Gray Matter In Abstinent Heroin Addicts, 126 (3) DRUG AND ALCOHOL 
DEPENDENCE 304 (2012). 
148 Connolly, supra note 68, at 3, 5. 
149 Id. at 5. 
150 Id. at 5-6. 
151 Snoek, supra note 87, at 185; Peele, supra note at 126, 98; Lewis, supra note 108, at 89-91. 
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Designating that all persons with SUD have an irreversibly diseased brain and will face a 
lifetime of struggle is not only unsupported by current evidence, but may contribute to 
helplessness and despair.152  Reframing expectations with hope can assist persons with SUD to 
see a valuable future, view themselves as agents of change, and believe they can develop the 
skills for reflection to “reverse, reknit, and regrow” new neurological pathways through alternate 
routines and habits leading to recovery.153  Research suggests multiple effective therapies such as 
contingency management, therapeutic communities, and social support programs may help 
patients reconnect with their vision for a valued future.154 
Agency, neurological recovery, and the concept of self-efficacy are crucial ingredients 
for persons with SUD to themselves believe in a different future.155  While intended as an 
extension of compassion, harm reduction policies that promote the use of alternate illicit 
substances such as marijuana or supervised consumption sites not only undermine the concept of 
self-efficacy and facilitate the circumstances for persons with SUD to continue inflicting self-
harm, but also relay the destructive and potentially self-fulfilling message that some persons with 
addiction are beyond recovery. 156 
                                                           
152 Id. 
153 Lewis, supra note 108, at 89-91 (discussing imagining a future valuable enough to pursue), 137-138 (compulsion 
and neurological changes in addiction are not immutable), at 159 (persons with addiction need motivation, insight, 
and perspective to want to move beyond addiction and reconnect with their lives). 
154 August Holtyn et al., Employment Based Abstinence Reinforcement Promotes Opiate and Cocaine Abstinence in 
Out-Of-Treatment Injection Drug Users, 47 JOURNAL OF APPLIED BEHAVIORAL ANALYSIS 681 (2014); Holtyn, supra 
note 125. 
155 Peele, supra note 126, at 100. 
156 Considering the impact of both availability and legal penalty, health policy that favors increasing access to other 
classes of recreational substances such as marijuana or advocates for “safe injection” facilities are not supported by 
current data.  Instead, both epidemiological research and addiction psychology suggests increasing legal 
permissibility and availability will increase rates of substance abuse and lower the probability of remission. See 
Nicholas Lau et al., A Safer Alternative: Cannabis Substitution as Harm Reduction, 34(6) DRUG AND ALCOHOL 
REVIEW 654 (2015) (discussing cannabis as an effective harm reduction method for persons who do not want to stop 
abusing drugs); see also Michelle Chen, New York Could Open the First Safe Injection Site in the U.S., THE NATION 
(Apr. 24, 2018), https://www.thenation.com/article/new-york-could-open-the-first-safe-injection-site-in-the-us/ 
(describing potential plans to open supervised injection facilities in New York City). 
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C. Why Terminology Matters: Physiological Dependence, Addiction, and Substance 
Use Disorder 
The considerations of whether persons with SUD would benefit from treatment, whether 
they relapse, and what factors influence these questions requires greater precision when 
describing both the population and the condition.  Research suggests not all persons with SUD 
progress to unremitting addiction, and not all persons with OUD specifically should be swept 
into the category of persons with an addiction but may encompass distinct populations that 
compels a different approach. 
Shifts in the Diagnostic and Statistical Manual: No More Distinct Categories to Describe 
Addiction  
  Both federal policy and diagnostic classifications have addressed the matter of 
terminology and how to address the concept of addiction and terminology.  Until recently, 
addiction scientists distinguished between physiological dependence and substance abuse or 
addiction.  Drugs including opioids may cause physical and psychological dependence resulting 
in symptoms of withdrawal which is distinct from addiction, or a compulsive and intense desire 
to continue using the drug even at the expense of serious adverse consequences. 157  Reuben 
Baler and Nora Volkow of NIDA also recognize that only a small portion (about 10%) of 
persons who abuse substances progress to addiction.158   
Although addiction is not a diagnostic classification, until 2013 the American Psychiatric 
Association in the Diagnostic and Statistical Manual (DSM) recognized two distinct categories 
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158 Volkow & Baler, supra note 67, at 559. 
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of substance abuse and substance dependence.159  Criteria for substance abuse entailed harmful 
use of substances that resulted in harm to others, such as neglecting life roles, hazardous use, 
legal problems, and interpersonal or social problems.160  To compare, substance dependence 
referred to harm to one’s self resulting from physical and physiological dependence, such as 
tolerance, withdrawal, using larger amounts of a substance, devoting more time to using the 
substance, experience of physical or psychological problems from using the substance, and 
repeated attempts to quit.161   
In 2013, The American Psychiatric Association published the DSM V, which merged two 
previously distinct categories into a singular category of substance use disorder,162 vastly 
increasing the breadth of the persons who may have developed a tolerance to a drug, experience 
withdrawal, and are trying to stop using the drug into the same broader category of a person with 
intractable addiction who experiences social and legal problems and may have no desire to 
discontinue the addiction.   
The Office of National Drug Control Policy’s Memorandum on Addiction Terminology 
 In 2017, Director of the Office of National Drug Control Policy (ONDCP) Michael 
Botticelli issued a Memorandum calling to modify key terminology relating to addiction.163  
According to ONDCP, the public associates disfavor with the terminology “substance abuser,” it 
provokes negative attitudes among health professionals, and it may deter persons who need 
treatment.164 Referencing the modification in the DSM, ONDCP asserted “substance use 
disorder” is the clinically accurate term, because drug “habit” and “drug abuse” incorrectly imply 
                                                           
159 Michael Norko & W. Lawrence Fitch, DSM-5 and Substance Use Disorders: Clinicolegal Implications, 42(4) 
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the person has a choice to stop, which causes confusion because the person instead requires 
treatment to stop or reduce his or her substance use to a “safer level.”165   
Both the modification in the DSM and the ONDCP’s call to relabel previously distinct 
categories has dramatic implications for considering how to address patient populations 
accurately and determining as a matter of health policy what course of clinical intervention is 
appropriate.  For example, the term opioid use disorder collapses both persons with intractable 
addiction to heroin and prescription opioids versus persons who developed physiological 
dependence to prescription opioids.  This has significant impact for the scenario when a person 
was prescribed an opioid and is unsuccessfully attempting to discontinue using it, but faces 
painful physical and physiological withdrawal and the prescribing clinician is unable or lacks 
appropriate resources to assist the patient to discontinue the medication.166  Physician Dr. 
Andrew Kolodny notes opioids produce both physical and psychological symptoms when a 
patient attempt to discontinue the medication.167  A patient may experience physical withdrawal 
symptoms such as nausea, vomiting, sweating, muscle aches, but also agitation, anxiety, 
insomnia and a feeling of “impending doom.”168 
Accurately Identifying the Patient Population and Its Needs: Iatrogenic Opioid Dependency 
ONDCP’s Memorandum also discounts pertinent differences among population groups 
based on type of substance abuse.  NIDA recognizes that heroin use is rare in prescription drug 
users, and only a very small percent (4%) of persons who have prescription opioid dependence 
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166 See Sontag, supra note 41 (Sontag describes various patients who sought medical care for ailments including 
back pain, sports injuries, fibromyalgia, and kidney surgery, received a prescription for opioids from their physician, 
attempted to stop the prescription, and struggled with withdrawal based on prescription dependence.  Sontag also 
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167 Kolodny, supra note 58, at 14. 
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begin abusing heroin.169  Of this population that switches from heroin from prescription opioids, 
these persons are frequently polysubstance abusers of other illicit drugs.170  Of persons who 
misused prescription opioids in the 2000s, 75% reported their first opioid was a prescription 
drug.171  Demographic characteristics based on race and socioeconomic status on a population 
level differ among persons abusing heroin and other opiates (younger men from minority races 
living in urban areas) versus persons with prescription opioid dependence (older white persons in 
rural and suburban areas).172 These demographic shifts have led to outcry in the media alleging 
racial bias as a motivating reason for approaching opioid dependency as a medical condition 
requiring treatment rather than a matter of public safety and crime.173  As described supra in Part 
I, even though substance abuse and crime may be interrelated, persons are not penalized for 
either physiological dependence on a substance or having an addiction, but their decision to 
commit a crime.  
These claims further ignore the crucial distinction the healthcare system played in 
creating a class of patients with iatrogenic opioid dependency. Patients use of, and dependence 
on, prescription opioids in many cases began with a legitimate therapeutic prescription after 
seeking medical care from a physician.174  As prescriptions for opioids nearly tripled from 1991 
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to 2011, overdose deaths also near tripled over the same time period.175  Physician Dr. Anna 
Lembke aptly describes the confluence of factors stemming from industry exerting influence on 
physicians to overprescribe opioids to more patients.176  This led to creating a new class of 
patients with iatrogenic opioid dependence: what Kolodny describes as a “perfect patient” 
attempting to discontinue a prescribed medication experiences who not only experiences acute 
withdrawal, but months of extended withdrawal with difficulty sleeping, irritability, and 
unrelenting depression.177 Without assessing the patient population and its specific needs, 
expanding the current treatment model would entail sweeping persons with iatrogenic 
physiological dependence into the same treatment category as persons with addiction. 
Parallels Between Opioid Marketing and Claims Relating to MAT 
Lessons from drug marketing promises that led to the opioid crisis highlight a number of 
considerations that are directly relevant when asking whether prescribing a different class of 
medications in MAT constitutes the most appropriate policy response.  In 2007, Purdue 
Frederick Company pled guilty to criminal charges of misbranding OxyContin with the intent to 
defraud or mislead, which is considered a felony under the Federal Food, Drug and Cosmetic 
Act, wherein Purdue paid $634.5 million in monetary sanctions.178  Though the substantive 
details of this case and allegations of ongoing deception179 are outside the scope of this 
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discussion, the case raises salient parallels of how financial interests can shape medical practice 
and perception of what constitutes appropriate medical care.180   
Purdue proffered a variety of claims that bear striking similarity to claims currently 
percolating in scientific and scholarly literature relating to maintenance medications utilized in 
MAT.  First, corporate interests expand the pool of potential patients and designate treatment as 
a medical need that should not be denied.181  This ignores research that shows pharmacological 
intervention may not be effective while other less risky modalities may provide benefit.182 
Second, corporate interests assert pharmacological intervention constitutes the most effective 
solution and downplay risk.  In educational materials, manufacturers may bolster these claims by 
specific promises that the medication is less likely to cause tolerance and withdrawal compared 
to other substances, is “less addictive,” does not cause euphoria, and is less likely to be abused or 
diverted.183  In the case of medications used in MAT, these are exactly the terms NIDA and 
SAMHSA uses to describe two medication used in MAT, methadone and buprenorphine, and 
distinguish them from other prescription opioids.  Few ask the pertinent question of whether the 
evidence indeed exists to support claims of appropriateness, safety, and perceived benefit.184  
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 In January 2019, media outlets published a full unredacted complaint Massachusetts 
Attorney General filed against Purdue Pharma.185  This lawsuit alleges, among other claims 
relating to fueling the opioid epidemic in the U.S., that Purdue Pharma actively formulated a 
strategy to capitalize on expanding into the “attractive market” of selling treatments for patients 
with OUD.186  Notably, Richard Sackler part of one of the co-founding families behind of Purdue 
Pharma, is listed as joint patent holder on  a new formulation of buprenorphine.187  According to 
the State’s Complaint, Purdue Pharma planned for “a joint venture controlled by the Sacklers to 
sell the addiction medication suboxone,” outlining Purdue Pharma’s business strategy Project 
Tango: “patients on opioids could now be used to sell treatment for opioid addiction.”188  Based 
on Project Tango’s projections, 40-60% of patients would relapse, which translated to long term 
use of a buprenorphine formulation.189  This unconscionable conflict of interest merits further 
scrutiny when examining the scope, prominence and promises of MAT.  
III. MEDICATION ASSISTED TREATMENT 
This section will describe the view set forth by NIDA, SAMHSA, and the Office of 
National Drug Control Policy that MAT constitutes the most effective method of treatment for 
OUD.  It will provide an overview of three types of FDA approved medication (1) methadone, 
(2) buprenorphine, (3) and naltrexone, including legal classification, prescribing requirements, 
and potential risks or adverse effects.   
 
 
                                                           
185 David Armstrong, OxyContin Maker Explored Expansion Into “Attractive” Anti-Addiction Market, ProPublica 
(Jan. 30, 2019), available at https://www.propublica.org/article/oxycontin-purdue-pharma-massachusetts-lawsuit-
anti-addiction-market. 
186 Pl.’s Am. Compl. At 151-54, Commonwealth v. Purdue Pharma Inc., No. 1884-cv-01808 (Jan. 2018). 
187 Armstrong, supra note 185. 
188 Commonwealth v. Purdue Pharma, supra note 186 at 154-55. 
189 Id. at 155. 
  
36 
A. The Prominence of MAT 
The Surgeon General’s Report on Alcohol, Drugs, and Health states there is “one clear 
conclusion:” if SUD constitutes a chronic but treatable disease, then it requires expanded medical 
intervention.190  In the U.S., the FDA has approved three classes of medications to treat persons 
with OUD in MAT: methadone, buprenorphine, and naltrexone.191  NIDA maintains medication, 
along with behavioral therapy constitutes the most effective treatment for opioid use disorder.192  
ONDCP goes further, asserting medication does not merely assist with psychosocial services, but 
is itself a central component of evidence-based practice.193 The American Society of Addiction 
Medicine (ASAM) issued specific Practice Guidelines regarding the use of medications in 
treating opioid use disorder, provides dosing guidelines, and recommends implementing a plan 
for psychosocial treatment in addiction to pharmacological treatment.194   
Methadone 
In the 1960s, physicians Drs. Vincent Dole and Marie Nyswander piloted the use of 
methadone as a replacement drug for a small population of persons with intractable heroin 
addiction.195  Dole and Nyswander hypothesized addiction could be reduced to biochemical 
deficiency, theorizing persons with intractable intravenous heroin addiction suffered from a 
metabolic disruption wherein they “needed narcotics in a visceral way.”196  By providing an 
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exceptionally high dose of a substitute opioid in a clinical setting, physicians could “correct” a 
“neurological derangement.”197  Methadone maintenance, according to Dole, was corrective but 
not curative.198 
Methadone is a synthetic full opioid agonist, which binds to and activates the same opioid 
receptors as heroin, morphine, and opioid pain medications.199  It is designed for a slower and 
more controlled release to prevent cravings and withdrawal symptoms over a longer time 
duration.200  NIDA maintains methadone does not produce euphoria at therapeutic doses, patients 
receiving methadone do not appear “high” based on their tolerance to the drug’s effects, and are 
able to function normally to attend school, work, and engage in activities of daily life. 201 
 Under the Controlled Substances Act, methadone is a Class II controlled substance, 
which means despite an accepted medical use, it has a high potential for abuse and may lead to 
severe psychological or physical dependence.202  The Controlled Substances Act requires 
practitioners who dispense, administer, or prescribe methadone or buprenorphine to register with 
the Drug Enforcement Administration.203  Practitioners also must maintain records of inventory 
to track prescribing for both methadone and buprenorphine as a mechanism designed to prevent 
diversion.204  When used in the context of opioid treatment, practitioners may only provide 
methadone through an Opioid Treatment Program (OTP) that is certified and complies with 
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requirements set forth by Substance Abuse and Mental Health Administration (SAMHSA).205  
With limited exceptions, providers at OTPs may only administer methadone to patients at the 
facility.  Federal regulations permit “take home” doses of methadone for weekends, holidays, 
and based on the provider’s discretion when reviewing a record of a patient’s treatment 
compliance.206   
 NIDA states health professionals have successfully used methadone for forty years. 207  In 
2009, Richard Mattick and colleagues reviewed studies examining the use of methadone 
maintenance versus no methadone maintenance for persons with opioid dependence.208  Mattick 
and colleagues found patients receiving methadone maintenance showed a higher rate of 
retention in treatment, reduced heroin use and concluded health professionals should support 
methadone maintenance for persons with heroin addiction.209   
 Use of methadone carries a variety side effects and risk of adverse events.  Side effects 
may include dizziness, sedation, nausea, vomiting, sweating, confusion, agitation, dysphoria, and 
insomnia.210 Risks also include life threatening QT prolongation (a heart arrhythmia) and similar 
to other opioid analgesics, administration of methadone even in the prescribed amount can cause 
respiratory depression and death.211   
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Methadone has unique pharmacological properties that require cautious administration.  
The analgesic effect of methadone lasts about 4 to 8 hours, but it remains in the body for 8 to 59 
hours, binding to tissues including the brain.212  In risk management materials, SAMHSA has 
warned the combination of methadone’s long half-life and slow elimination can result in the fatal 
accumulation of methadone in patients, leading to iatrogenic overdose.213  Methadone also may 
exert neurotoxic effects, reduce gastrointestinal motility leading to constipation, suppress the 
immune system, and impact the endocrine system which may manifest as insulin imbalances, 
impotence, erectile dysfunction, amenorrhea, or infertility.214  The FDA approved package insert 
for Methadose, the oral liquid used by OTPs also provides a warning statement that methadone 
may impair the patient’s ability to drive or operate heavy machinery.215   
Despite the profile of risks and adverse events, health professionals maintain “essential 
questions of safety and efficacy have been definitively answered” and methadone offers a safe 
and effective treatment for persons with addiction because it normalizes patient function with 
minimal psychoactive impairment.216  
Buprenorphine 
Buprenorphine is a partial opioid agonist, and binds to the same receptors as other 
opioids but activates them less strongly.217  It is also designed to reduce cravings and withdrawal 
                                                           
212 Methadone, supra note 201; Methadose, supra note 199, at 28.  
213 Id.; Minimize Liability, Manage Risk, Ensure Patient Safety: Effective Strategies in Outpatient Methadone 
Treatment Webinar, SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION (Aug. 26, 2009), 
https://ireta.org/wp-content/uploads/2014/11/Clinical-Guidelines-and-Liability-Prevention-6.pdf (hereinafter 
“SAMHSA Minimize Liability”). 
214 Methadose, supra note 199, at 1, 3-4. 
215 Id. at 13. 
216 Vincent Dole, What Have We Learned From Three Decades of Methadone Maintenance Treatment?, 13(1) 
DRUG AND ALCOHOL REVIEW 3-4 (1994); Herbet Kleber, Methadone Maintenance Four Decades Later: Thousands 
of Lives Saved, But Still Controversial, 300(19) JAMA 2302 (2008). 
217 Medications to Treat Opioid Use Disorder, supra note 8, at 5; Subutex [Package Insert], RECKITT BENKISER 
PHARMACEUTICALS INC. (2010), 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020732Orig1s010lbl.pdf; Andraka-Christou, supra note 
36, at 193 (hereinafter “Subutex”).  
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at therapeutic doses, and NIDA states it does produce euphoria based on patient tolerance and 
dosage.218  Some formulations of buprenorphine combine buprenorphine with naloxone, an 
opioid antagonist to function as an abuse deterrent.219  As a partial agonist, it is designed to block 
the high from additional opiates and SAMHSA asserts buprenorphine carries a lower risk of 
abuse or diversion based on its “ceiling effect.”220  SAMHSA states buprenorphine assists 
persons with opioid abuse disorder regain normal, healthy lives, and permits patients to function 
normally.221    
Under the Controlled Substances Act, buprenorphine is a Class III controlled substance, 
which means the DEA has determined it has less potential for abuse than a Class II substance 
such as methadone.222 Buprenorphine has an accepted medical use, and abuse of it may lead to 
moderate or low physical dependence and high psychological dependence.223  Buprenorphine 
comes in several forms, including daily pills, a sublingual film, and a sixth month injection.224  
Physicians may prescribe buprenorphine through an OTP certified by SAMHSA or through 
physician offices for addiction treatment pursuant to specific requirements.225  The Drug 
Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act permits 
physicians, qualifying nurse practitioners, and physicians’ assistants to obtain a waiver from the 
Secretary of Health and Human Services to prescribe and dispense buprenorphine in outpatient 
                                                           
218 Medications to Treat Opioid Use Disorder, supra note 8, at 5, 12; Buprenorphine, Medication Assisted 
Treatment, SUBSTANCE ABUSE AND MENTAL HEALTH ADMINISTRATION, https://www.samhsa.gov/medication-
assisted-treatment/treatment/buprenorphine (hereinafter SAMHSA Buprenorphine”). 
219 SAMHSA Buprenorphine, supra note 218; see also Andraka-Christou, supra note 36, at 193-194 (discussing 
different formulations of buprenorphine). 
220 Id. 
221 The Facts About Buprenorphine, SUBSTANCE ABUSE AND MENTAL HEALTH ADMINISTRATION, 
https://store.samhsa.gov/system/files/sma14-4442.pdf at 5, 11. 
222 Controlled Substances Act, 21 U.S.C. § 812(b)(3); Buprenorphine, Office of Diversion Control, DRUG 
ENFORCEMENT ADMINISTRATION (July 2013), 
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224 Buprenorphine, Medication Assisted Treatment, supra note 218. 
225 GAO Report, supra note 205, see Table 2 at 10. 
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settings, such as physician offices rather than traveling to receive a daily dose of medication at 
an OTP.226   
Proponents of MAT and buprenorphine note that eliminating the need for daily clinic 
visits expands access for patient to receive medication used in MAT.227  Patients treated with 
buprenorphine are more likely to stay in treatment compared to patients receiving placebo, and 
less likely to abuse opioids than patients receiving no form of treatment.228 Comparisons 
demonstrate similar rates of efficacy for either methadone or buprenorphine when the prescribed 
at a sufficient dose and duration.229   
Side effects from buprenorphine include headache, nausea, vomiting, sweating, 
constipation, withdrawal symptoms, anxiety, depression, and insomnia.230  Additional adverse 
risks include hepatic events, respiratory depression, and overdose, which is more likely to occur 
if a patient combines buprenorphine with central nervous system depressants such as alcohol or 
benzodiazepines.231  The FDA approved package insert for one formulation, Subutex, carries 
specific warnings of its potential for dependence and abuse along with a warning Subutex may 
impair the patient’s ability to drive or operate machinery.232  
Naltrexone 
Naltrexone is an opioid antagonist, which blocks the effects of opioids by binding to 
opioid receptors which is designed to block euphoria from opioid drugs.233  It may also block 
                                                           
226 21 U.S.C. § 823 (g)(2); 21 C.F.R. § 1306.07; 42 C.F.R. § 8.610 et seq. 
227 Medications to Treat Opioid Use Disorder, supra note 8, at 5-6; Andraka-Christou, supra note 36, at 193-194. 
228 Medications to Treat Opioid Use Disorder, supra note 8, at 8-9. 
229 Id. at 10.  
230 Subutex, supra note 217, at 1, 7, 8. 
231 Id. at 5-6. 
232 Id. at 4-5. 
233 Medications to Treat Opioid Use Disorder, supra note 8, at 10; Vivitrol [Package insert], ALKERMES, INC.  
(2010), https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021897s015lbl.pdf; The Facts About 
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http://adaiclearinghouse.org/downloads/Facts-About-Naltrexone-for-Treatment-of-Opioid-Addiction-28.pdf 
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endogenous opioid peptides.234  Naltrexone is designed to prevent relapse following 
detoxification from opioids.235  If a patient begins taking naltrexone prior to detoxification, the 
patient may experience withdrawal symptoms.236  Naltrexone comes in daily pill form or a once 
monthly injection by the brand name Vivitrol.237  Naltrexone is not designed to stop drug 
cravings, is not designed as an aversive therapy, and a patient may be able to surmount the 
pharmacological barrier.238  If a patient abuses opioids during treatment with naltrexone, the 
patient’s tolerance for the opioid may decrease, which increases the risk of overdose.239   
Naltrexone is not an opioid and is not classified under the Controlled Substances Act, so 
it may be prescribed by any physician, whether through an OTP or a physician office as part of 
MAT. 
NIDA states there is insufficient evidence that oral naltrexone is an effective treatment 
for opioid use disorder, and instead recommends injectable naltrexone, which one clinical trial 
demonstrated decreased opioid abuse and improved treatment retention.240  Research shows 
fewer patients utilize naltrexone compares to methadone or buprenorphine, low patient 
adherence to naltrexone and high rates of attrition.241  One research study by Dr. Joshua Lee and 
colleagues compared the effectiveness of a buprenorphine-naloxone combination against 
injectable naltrexone, measuring treatment retention and opioid abuse in a research trial, finding 
                                                           
at 3 (hereinafter “Vivitrol”).  
234 Vivitrol, supra note 233, at 19. 
235 Id. 
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238 Vivitrol, supra note 233, at 1, 19;  at 8-9 (discussing patients who “continue to test the blockade” by abusing 
opioids). 
239 Id. at 2. 
240 Medications to Treat Opioid Use Disorder, supra note 8, at 10. 
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similar outcomes for each metric.242  Physicians who specialize in addiction, including Dr. 
Andrew Kolodny, highlight a substantial percent (28%) of study subjects withdrew from the 
initial clinical trial during the detoxification phase, leaving these patients susceptible to relapse 
and overdose and potentially misrepresents the conclusion that both medications offer similar 
rates of efficacy.243        
Side effects from injectable naltrexone include nausea, vomiting, injection site reaction, 
muscle pain, insomnia, and hepatic abnormalities.244  Additional adverse events include hepatic 
toxicity, injection site necrosis, eosinophilic pneumonia, depression, and suicidality.245 The FDA 
approved package insert for one formulation, Vivitrol, also warns of risk of dizziness, sleepiness, 
and the potential to impair the patient’s ability to drive or operate machinery.246 
B. “Consensus” on the Efficacy of MAT 
Federal policy asserts there is “consensus”247 in the medical community that MAT plays 
a critical role in the treatment of persons with opioid use disorder and it constitutes the most 
effective form of treatment.248  NIDA states that patients receiving MAT are more likely to 
reduce their use of opioids, remain in treatment, and reduce their involvement in the criminal 
justice system.249  The Surgeon General notes MAT assists persons with an opioid use disorder 
                                                           
242 Joshua Lee et al., Comparative Effectiveness Of Extended-Release Naltrexone Versus Buprenorphine-Naloxone 
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to control their symptoms of withdrawal and craving and helps patients return to a healthy life.250  
To achieve the best outcomes, providers should use MAT in conjunction with behavioral therapy 
measures.251  SAMHSA recommends patients should use medications as long as it provides 
benefit, cautioning that patients who discontinue medication generally return to illicit opioid use 
and healthcare policy should prioritize patient access, utilization, and expansion of MAT. 252  
NIDA, SAMHSA, and the Office of National Drug Control Policy253 each issued specific 
statements asserting it is a “misconception” that MAT substitutes one substance use disorder for 
another, lamenting this perspective has hindered the adoption of evidence-based treatments.254 
SAMHSA maintains patients using replacement opioids as part of MAT receive a safe and 
controlled level of medication and the appropriate dose exerts “no adverse effects on a person’s 
intelligence, mental capability, physical functioning, or employability.”255  NIDA asserts patients 
receiving replacement opioid agonists do not experience euphoria because they have developed a 
tolerance.256 In a 2016 report, the Government Accountability Office stated abstinence-based 
treatment often fails, is less effective than MAT, and argued hesitation or opposition to MAT 
indicates a “lack of understanding” of addiction and inaccurate beliefs.257 Friedmann and Suzuki 
argue extensive research shows pharmacotherapy constitutes the most effective treatment 
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specifically for OUD and should constitute the first line standard of care, replacing any treatment 
programs that offer detoxification and therapy.258  
IV. CRITICAL ANALYSIS OF THE EVIDENCE SUPPORTING MAT 
 MAT may indeed work for some patients, particularly if the patient tolerates the 
medication without adverse effects and the provider offers comprehensive behavioral treatment.  
But promoting MAT as blanket federal policy, or even as a first line long term treatment, 
requires critical analysis. This section describes how claims pertaining to MAT’s efficacy are 
supported by partial metrics and federal policy has downplayed problematic outcomes such as 
high rates of continued opioid and polysubstance abuse, potential for dependence or addiction to 
the replacement medication, and risk of serious physical and neurological outcomes.  Financial 
entanglements between industry and government appear to exert influence on federal policy 
supporting the expansion of MAT for all persons with OUD, yet an independent review by the 
Cochrane Collaboration distinguished little evidence exists for providing pharmacotherapy to all 
persons with opioid dependence. 
A. Declarations of MAT’s Success Downplay Important Metrics 
  Statements asserting that MAT constitutes the most effective treatment contains a 
number of potentially misleading caveats: some studies support this proposition by comparing 
MAT to detoxification259 rather than treatment and do not address the significance of continued 
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substance abuse.260  One commonly cited study by Karen Sees and colleagues did compare MAT 
against treatment (where the detoxification group was required to attend therapy sessions) and 
reported MAT increased retention and reduced opioid use.261  Yet this claim requires further 
examination: despite a slight decrease in opioid use among the MAT group, opioid use in both 
groups remained “consistently high,” and both groups continued polysubstance abuse of both 
opioids and cocaine, which Sees and colleagues noted “remains a concern.”262  Though rates of 
substance abuse vary over time and by study, rates of continued opioid abuse among subjects 
enrolled in MAT range from over 50% to 89.5%, even after being enrolled in MAT for several 
months.263  Indeed, Nielsen and colleagues concluded there appears to be no significant 
difference in days of unsanctioned opioid use among study groups who receive MAT versus those 
who do not.264  
Research cited to support the efficacy of MAT also demonstrates consistently high rates 
of other types of polysubstance abuse across study groups, including among subjects receiving 
MAT.265  Additional research shows subjects enrolled in MAT abuse multiple other licit and 
illicit substances in addition to opioids including alcohol, cocaine, and cannabis.266  Sees and 
colleagues assert rates of polysubstance abuse do not appear to be related to inadequate dosing of 
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maintenance medication.267 Discounting significant continuing opioid or polysubstance abuse 
among persons enrolled in MAT should trigger a re-assessment of blanket declarations of 
efficacy. 
Both media reports and case law bolster these data showing patients enrolled in MAT 
continue to abuse opioids and or engage polysubstance abuse.  One patient who was enrolled in 
MAT and received a prescription for Suboxone (buprenorphine/naloxone) commented it “did 
nothing but prolong my death…I was just taking other drugs with it and it was really just a Band-
Aid.”268  Similarly, investigations into OTPs by the New York Times shared a father’s story, who 
reported despite his son’s assertion that Suboxone worked for him, his son overdosed five times 
by abusing other substances while in MAT, eventually succumbing to a fatal overdose.269   
Case law portrays similar findings: in Taylor v. Smith, Glenda Ennis, a patient in a 
methadone maintenance program, stated repeatedly she had no desire to stop any of her 
polysubstance abuse, and continued to abuse cannabis and illicit benzodiazepines while enrolled 
in MAT.270  Similarly, in Lingren v. Pinnacle Recovery Services, methadone maintenance patient 
Vanessa Brigan continued illicit substance abuse by not only drinking her daily dose of 
methadone, but injecting additional doses of methadone, and simultaneously abusing cannabis.271  
The court in Taylor v. Smith concluded MAT facilitated Ennis to receive methadone not in lieu 
of illegal drugs, but in addition to them.”272   
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Many studies compare retention in treatment as a metric of success, but presuming 
treatment retention equates to success reveals conflicting and troubling evidence.  While Mattick 
and colleagues review asserted that MAT constitutes an effective intervention, it found no 
statistically significant differences in criminal involvement or mortality.273  Several studies 
conflict with the Surgeon General’s claims that MAT helps persons return to a productive life, 
finding continued psychosocial dysfunction and rates of marginal employment or 
unemployment.274  One significant barrier to employment and psychosocial functioning rests 
upon patients’ ability to conduct activities of daily living, such as driving, working, going to 
school, and engaging in family life without significant impairment such as experiencing 
euphoria, craving, and symptoms of withdrawal.275  
B. Evidence Does Not Support the Proposition that MAT Permits Patients to 
Function Normally and Promotes Recovery  
MAT Does Serve as Medically Sanctioned Substitute Opioid with Serious Risks for Dependency 
 Despite rhetoric in federal policy asserting MAT does not constitute replacing or 
substituting one SUD for another, these claims are not supported by pharmacology, legal 
classification by the DEA, or numerous first person patient reports.  As opioid agonists, both 
methadone and buprenorphine occupy the same receptors as other substances such as heroin or 
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oxycodone.276  Though NIDA denies patients receiving methadone and buprenorphine 
experience euphoria, both FDA and DEA product labeling caution against the opposite: both 
controlled substances are capable of producing significant euphoria even in persons with 
tolerance.277 In a graph illustrating sustained activation of opioid receptors (euphoria), NIDA 
compares the relative euphoria of heroin to methadone, buprenorphine, and naltrexone.278  The 
graph shows buprenorphine as a partial opioid agonist produces less euphoria relative to heroin, 
but also shows methadone produces the same level of euphoria as heroin, but sustains this 
activation for a longer duration relative to heroin.279  Patient reports collected in research, 
SAMHSA provider educational materials,280 and patient accounts reported in the media confirm 
patients request higher doses specifically to experience euphoria,281 become “desperate”282 in 
seeking more agonist medication in greater dosages, and allege “it’s easy to game the 
system…[and receive] as much as you want.”283   
Research also supports the premise that MAT may not reduce cravings: many persons 
enrolled in MAT abuse the prescribed agonist itself (e.g. injecting methadone or buprenorphine) 
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in addition to continuing concurrent polysubstance abuse.284  This suggests a deficiency in the 
premise of MAT – patients are still experiencing a compulsion and drive to abuse opioid 
agonists, including the prescribed opioid agonist, for pharmacological effect.  Indeed, in 2016, an 
opinion piece the New York Times described patients attempting recovery through MAT who 
became dependent on Suboxone, and developed an addiction to the medication itself.285  
 Patients are also diverting the medication into the illicit market.286  Despite NIDA’s 
assertion that diversion is rare and merely occurs for therapeutic purposes,287 recent research,288 
the Drug Enforcement Administration (DEA),289 and the Department of Justice290 suggests 
diversion may constitute an increasing problem.291  In 2009, the National Forensic Laboratory 
Information System of the DEA published a special report demonstrating the explosion of 
diverted methadone and buprenorphine between 2003 and 2008 during the period when patient 
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enrollment in MAT increased in response to opioid dependency.292  During this time, diversion 
of buprenorphine increased 250-fold into the illicit market.293 
Finally, patients who want to discontinue maintenance medication may find their 
treatment facility or individual practitioner may not provide a clear plan of how to stop.294  
SAMHSA specifically recognizes many OTPs do not provide a pathway for its patients to go 
medication free based on a justification of “poor outcomes” and acknowledges opioid agonists 
do result in patient dependence.295  Patients feel resigned to taking a maintenance medication 
“maybe forever” according to one physician because if they stop, they encounter severe 
symptoms of withdrawal and become physically sick.296 
MAT Can Produce Physical, Neurological, and or Psychological Harm That Hinders Recovery 
 The extensive and serious adverse effects for each of the three classes of medications 
used in MAT should not be dismissed as infrequent and may influence patients’ ability to engage 
                                                           
292 DRUG ENFORCEMENT ADMINISTRATION, Special Report: Methadone and Buprenorphine, 2003-2008, 1-2, 4-5, 10  
(2009), https://www.deadiversion.usdoj.gov/nflis/methadone_buprenorphine_srpt.pdf; see also Emergency Visits 
Involving Buprenorphine, supra note 291. 
293 DRUG ENFORCEMENT ADMINISTRATION, supra, at 1–2; see also Laura Ungar, Rogue Doctors Exploit Loopholes 
to Let a Powerful Drug ‘Devastate a Community,’ COURIER JOURNAL (June 8, 2017), https://www.courier-
journal.com/story/news/investigations/2017/06/08/rogue-doctors-hands-medicine-designed-treat-addiction-turns-
into-new-habit/98522426/ (quoting Kentucky Attorney General Andy Beshear who compares Suboxone clinics to 
the “second coming of pill mills” and reports the Attorney General’s Office has more complaints than it can count 
relating to illegal diversion and sale of buprenorphine products used in MAT). 
294 Julie Harris & Karen McElrath, Methadone as Social Control: Institutionalized Stigma and the Prospect of 
Recovery, 22 QUALITATIVE HEALTH RES. 810, 816 (2012) (providing interviews with methadone patients stating 
their desire to discontinue methadone, fearing long term use of methadone and its consequences, and a desire to 
reduce or stop methadone but experiencing no support to do so and encountering a blanket policy of retaining 
patients on methadone). 
295 SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION, Federal Guidelines for Opioid Treatment 
Programs, HHS Publication No. (SMA) PEP15-FEDGUIDEOTP, 23, 25 (2015) (opioid agonist medications will 
themselves produce dependence) (many OTPS do not provide a pathway for a medication free state due to 
“notoriously poor outcomes”). 
296 Deborah Sontag, At Clinics, Tumultuous Lives and Turbulent Care, NEW YORK TIMES (Nov. 17, 2013), 
https://www.nytimes.com/2013/11/18/health/at-clinics-tumultuous-lives-and-turbulent-care.html (a physician 
reporting that new patients ask how long they will stay on buprenorphine, then stop asking when they realize the 
answer is “maybe forever”); Jose Del Real, Opioid Addiction Knows No Color, But Its Treatment Does, NEW YORK 
TIMES (Jan. 12, 2018), https://www.nytimes.com/2018/01/12/nyregion/opioid-addiction-knows-no-color-but-its-
treatment-does.html (providing a quote from a methadone patient stating, “I wish I didn’t have to come here every 
day, but I have to. If you don’t, you’re sick. You wake up sick.” (emphasis added)). 
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in activities of daily life.  In one study, over half of patients enrolled in methadone maintenance 
programs experienced depression, fatigue, and headaches, which negatively impact patients’ 
subjective assessments of quality of life.297 
Research suggests both opioid agonist and opioid antagonist medications used in MAT 
also pose risks to neurological and or psychological functioning.  
Wei-Che Lin and colleagues demonstrated patients enrolled in MAT who received an 
opioid agonist experience prominent adverse effects on multiple cognitive functions, experience 
increased rates of depression and suicide, and experience a lower quality of life.298  Opioid 
agonists negatively impact memory processing, impair short term memory, impair visuo-spatial 
attention, reduce cognitive speed.299  Research shows opioid agonists produce changes in both 
white matter and gray matter in the brain, resulting structural and functional abnormalities.300  
Chronic exposure to opioid agonists may lead to apoptosis (death) of neuronal cells and 
demyelination (impaired connectivity within the brain’s synapses), which has been connected to 
behaviors including impulsivity, lack of self-control, and intolerance for cognitive complexity.301  
Notably, research correlates this neurological damage to duration and dose of MAT, not pre-
existing differences or damage from illicit opioid abuse.302  Wei Li and colleagues summarize 
                                                           
297 Janie Sheridan et al., Health Problems and Help-Seeking Activities of Methadone Maintenance Clients and 
Aukland Methadone Services: A Potential for Community Pharmacy Expansion, 2(25) HARM REDUCTION J. 25, 25-
29 (2005). 
298 Wei-Che Lin et al., White Matter Abnormalities Correlating With Memory and Depression In Heroin Users 
Under Methadone Maintenance Treatment, 7 PLOS ONE 1, 7-8 (2012); see also Mintzer & Stitzer, Cognitive 
Impairment in Methadone Maintenance Patients, 67 DRUG & ALCOHOL DEPENDENCE 41, 41, 45-47 (2002) (finding 
patients enrolled in MAT had significantly worse performance than controls on tests for memory and cognitive 
speed); Shane Darke et al., Comparative Patterns of Cognitive Performance Amongst Opioid Maintenance Patients, 
Abstinent Opioid Users and Opioid Nonusers, 126 DRUG AND ALCOHOL DEPENDENCE 309 (2012) (patients enrolled 
in MAT had worse cognitive performance than both controls and former opioid users who were not abstinent). 
299 Id. 
300 Wei Li et al., Methadone Induced Damage To White Matter Integrity in Methadone Maintenance Patients: A 
longitudinal Self-Control DTI Study, 6 SCI. REPS. (2016). 
301 Li, supra note 300, at 2, 5; Darke, supra note 298, at 309; Mintzer & Stitzer, supra note 265, at 46-47; Lin, supra 
note 298, at 1, 7. 
302 Li, supra note 300, at 3-4; Darke, supra note 298, at 312; Lin, supra note 298, at 1, 7. 
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these findings as evidence that MAT induces a type of brain disease that may substantially 
impair enrolled patients.303  This research suggests MAT does not promote neurological 
recovery, but rather extends neurological dysfunction and may hinder behavioral therapy options 
that rely on new neurological growth, cognitive judgment, and discernment. 
 Opioid antagonist naltrexone’s inherent pharmacology likely impacts low adherence 
because, as an opioid antagonist, it may block the effect of endogenous opioids, endorphins, and 
enkephalins.304   Patients may be more likely to experience pain, depression, and thoughts of 
suicidality.305  Research shows naltrexone blocks or reduces the joy from life activities: such as 
the warmth of feeling connected to others, pleasure from delicious food, and a positive mood 
from exercise.306 Activities that provide alternate outlets such as exercise307 and therapeutic 
communities308 show excellent promise as potential therapies to reconnect and engage.  Yet, 
patients who adhere to naltrexone treatment may encounter difficulty in attempting to find 
alternate strategies, goals, and activities if they find their activities lack purpose and joy. 
 
 
                                                           
303 Li, supra note 300, at 5. 
304 Maia Szalavitz, How Safe Is America’s Hottest Heroin Addiction Treatment?, VICE (July 26, 2017), 
https://www.vice.com/en_us/article/7x9ypq/how-safe-is-americas-hottest-heroin-addiction-treatment.   
305 Id.; Rebecca Price et al., Opioid-Receptor Antagonism Increases Pain And Decreases Pleasure In Obese And 
Non-Obese Individuals, 233 PSYCHOPHARMACOLOGY 3869, 3869-70, 3875-77 (2016). 
306 Szalavitz, supra note 304; see Price et al., supra note 305, at 3869–70, 3874, 3876–77 (describing how opioid 
antagonists may increase pain, reduce pleasure, and contribute to depression); M. Daniel et al., Opiate Receptor 
Blockade by Naltrexone and Mood State After Acute Physical Activity, 26 BRIT. J. SPORTS MED. 111, 111, 113–14 
(1992) (discussing exercise generally induces a mood state of being more calm, relaxed and pleasant, and reduces 
depression, anger, and anxiety, yet naltrexone blocks these positive effects of exercise on mood state); Tristen 
Inagaki et al., Blocking Opioids Attenuates Physical Warmth-Induced Feelings of Social Connection, 15 EMOTION 
494, 494–500 (2015) (discussing how naltrexone reduces subjective feelings of social warmth and feelings of social 
connection and bonding). 
307 Mark Smith & Wendy Lynch, Exercise and a Potential Treatment for Drug Abuse: Evidence from Preclinical 
Studies, 2 FRONTIERS IN PSYCHIATRY 1 (2012). 
308 August Holtyn et al., Employment-Based Abstinence Reinforcement Promotes Opiate and Cocaine Abstinence in 
Out-of-Treatment Injection Drug Users, 47 J. APPLIED BEHAV. ANALYSIS 681, 681–82 (2014). 
  
54 
C. Financial Conflicts of Interest Have Significantly Driven Expansion of MAT 
Benedikt Fischer of the Centre for Addiction and Mental Health highlights the impact of 
corporate involvement in Canadian federal policy promoting MAT as a first line treatment 
despite lack of evidence for this patient population and serious adverse effects.309  In other 
scholarship, I’ve noted the strong financial conflicts of interest between clinical care standards 
and prescribing practices, and similar financial interests appear to influence federal policy here in 
the U.S.310  The American Society of Addiction Medicine that provides clinical guidelines for 
three types of maintenance medications as appropriate treatment choices (rather than alternate 
forms of comprehensive treatment) receives industry funding from multiple manufacturers of 
medications used in MAT.311  Industry funding may impact prescribing and policy to promote 
both opioid agonists and opioid antagonist medications.   
The New York Times reported on the public private partnership between NIDA and 
Reckitt Benkiser to conduct clinical trials on buprenorphine, which NIDA and the ONDCP 
viewed as an improvement to methadone.312  Charles O’Keefe, a former White House Drug 
Policy advisor also involved with Reckitt Benkiser, lobbied Congress to amend federal law to 
facilitate increased prescriptions for buprenorphine.313  States began to offer financial incentives 
or subsidies to increase the pool of providers, which correlated with more individual practitioners 
                                                           
309 Benedikt Fischer et al., Treatment of Prescription Opioid Disorders in Canada: Looking at the ‘Other 
Epidemic’?, SUBSTANCE ABUSE TREATMENT, PREVENTION & POL’Y (2016). 
310 Katherine Drabiak, The Impact of a Developing Regulatory Framework Governing LDTs in Precision Oncology: 
Re-Envisioning the Clinical Risk Assessment Paradigm, 13 JOURNAL OF HEALTH AND BIOMEDICAL LAW 1, 5-56 
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issue conclusions despite lack of support from scientific evidence). 
311 ASAM’s 2018 Corporate Roundtable included donations from Indivior (Suboxone), Alkermes (Vivitrol), 
Mallinckrodt (Methadose).  See 2018 Corporate Roundtable Members, AMERICAN SOCIETY OF ADDICTION 
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312 Sontag, supra note 269.  
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and OTPs offering buprenorphine.314  Entanglement between industry and federal policy has 
overshadowed concerns initially raised by the DEA and FDA pertaining to potential for 
dependency and diversion relating to buprenorphine.315  MAT increases profit not only for the 
pharmaceutical sector,316 but for physicians317 and OTPs, which have emerged as one of the most 
profitable sectors in healthcare with high profit margins.318   
According to the Center for Responsive Politics, in 2016 Alkermes spent $4.4 million for 
aggressive lobbying to brand Vivitrol (naltrexone) as a “nonaddictive medication” alternative to 
opioid agonists.319  Marketing to law enforcement and policymakers, Alkermes drafted sample 
state legislation permitting community corrections grant priority for programs that offer 
alternative sentencing programs, which may include “nonaddictive medication” for opioid 
dependency320 and marketed Vivitrol directly to drug court professionals as a method to directly 
expand its market reach.321   
                                                           
314 Id.; see also Christina Andrews et al., Adoption of Evidence-Based Clinical Innovations The Case of 
Buprenorphine Use by Opioid Treatment Programs, 71(1) MEDICAL CARE RESEARCH AND REVIEW 43 (2014) 
(finding that buprenorphine use increased 24% for detoxification and 47% for maintenance therapy between 2005 
and 2011 and was correlated with coverage by private insurance or state subsidies). 
315 Sontag, supra note 269 (writing the FDA and DEA were not initially convinced that buprenorphine has less 
abuse potential than other opioid agonists, which relates to the potential for individual abuse and diversion). 
316 Christopher Moraff, Suboxone Creator’s Shocking Scheme To Profit Off of Heroin Addicts, THE DAILY BEAST 
(Oct. 5, 2016), https://www.thedailybeast.com/suboxone-creators-shocking-scheme-to-profit-off-of-heroin-addicts 
(describing Reckitt Benkiser’s advertising strategies to promote Suboxone and retain market share after the patent 
for Suboxone expired in 2009). 
317 Watchdog Warns About Replacing Opioid Epidemic With a Psychotropic One, PR NEWSWIRE (Sept. 26, 2017), 
https://www.prnewswire.com/news-releases/watchdog-warns-about-replacing-opioid-epidemic-with-a-psychotropic-
one-300525829.html. 
318 Swisher, supra note 281; Wickersham & Basey, supra note 174, at 14; Mary Wickersham & Stephanie Basey, Is 
Accreditation Sufficient? A Case Study and Argument for the Transparency When Government Regulatory Authority 
is Delegated, 39(2) JOURNAL OF HEALTH AND HUMAN SERVICES ADMINISTRATION 245 (2016) at 247 (stating 
income and operating statistics for one clinic would yield annual revenue at $4 million).   
319 Jake Harper, A Drugmaker Tries to Cash In On the Opioid Epidemic, One State At A Time, NPR (June 12, 2017), 
https://www.npr.org/sections/health-shots/2017/06/12/523774660/a-drugmaker-tries-to-cash-in-on-the-opioid-
epidemic-one-state-law-at-a-time. 
320 Naltrexone is currently the only “nonaddictive” medication.  Id. 
321 Jake Harper, To Grow Market Share, A Drugmaker Pitches Its Product To Judges, NPR (Aug.3, 2017), 
https://www.npr.org/sections/health-shots/2017/08/03/540029500/to-grow-market-share-a-drugmaker-pitches-its-
product-to-judges. 
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The criminal justice setting specifically warrants special consideration based on the 
court’s influence and potential for coercion.  If offenders do require treatment, it must be 
evidence-based on appropriate outcome data, not financial entanglements and misleading 
metrics.  According to the World Health Organization, implementing any medication 
requirement in the criminal justice setting as a condition of parole or probation triggers serious 
human rights considerations.322  Financial entanglements, forceful lobbying, and the unique 
pharmacological profiles of medications used in MAT warrant inquiry whether these 
medications would in fact be effective, humane, and ethically appropriate compared to alternate 
models for the criminal justice setting such as HOPE or treatment alternatives.323 
D. Expanding MAT to all Persons with Opioid Use Disorder is Not Supported by 
Current Evidence 
 In Dole and Nyswander’s work, MAT using methadone began an experimental method to 
reduce mortality and relative illicit drug abuse among persons with intractable heroin addiction.  
Mattick and colleague’s review of research examining outcomes of patients enrolled in MAT 
used studies of patients with a heroin addiction, not patients with other types of OUD.324  In 
2016, the Suzanne Nielsen and colleagues published a review of studies that focus on the more 
precise question of whether MAT is effective for persons with OUD.325  Nielsen and colleagues 
found “very limited studies” and low to moderate quality evidence supporting the use of 
pharmacotherapy for opioid dependence.326  Notably, Nielsen and colleagues also reiterated that 
                                                           
322 WORLD HEALTH ORGANIZATION, supra note 64, at 233-234 (WHO warns against legally coerced treatment and 
the human rights issues raised by using the state’s policy power to force treatment on persons, stating the treatment 
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persons with heroin addiction appear to differ in important ways from persons with an opioid use 
disorder.327  
 Benedikt Fischer echoes Nielsen and colleague’s finding, asserting many persons with 
OUD are characterized by clinically relevant differences such as short-term or tangential 
involvement with prescription misuse.328  Fischer and colleagues predict adverse effects from 
MAT such as negative neurological changes, depression, and mortality will create a new 
epidemic of iatrogenic harm from medical intervention and assert evidence instead supports an 
individualized stepped approach where many patients would benefit from medication taper 
supported by behavioral therapy.329  
The evidence described above outlines numerous deficiencies supporting the proposition 
that MAT constitutes a safe, effective, and appropriate solution for either addiction or 
physiological dependence. 
V. Shortcomings Of Current Opioid Treatment Programs And Implications For Public 
Health And Safety  
This section will consider the implications of expanding MAT to all persons with Opioid 
Use Disorder by examining massive shortcomings relating to the regulation of Opioid Treatment 
Providers (OTPs), discrepancies in treatment quality, and why case law compels a fresh 
examination of the current treatment paradigm.     
A. Glimpses of a Problem: OTP Noncompliance and Substandard Care 
Recent media report, lawsuits, and case law suggest the current framework for MAT may 
pose serious health risks to both patient well-being and public safety.  Multiple reports describe 
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patients enrolled in MAT have died from either actively overdosing,330 or died from iatrogenic 
overdose wherein the patient ingested an opioid agonist as prescribed and died from medication 
toxicity.331  Compliance investigations and survey research of OTPs reveal some patients are 
enrolled in more than one OTP facility and receive multiple prescriptions, but physicians or OTP 
facilities do not check prescription drug monitoring databases.332  Media reports have also 
highlighted concerns relating to the sufficiency of treatment provided at OTPs, such “dose and 
go” treatment center that line up patients to receive medication but fail to provide behavioral 
therapy or counseling despite a federal requirement to do so.333  Across the country, media 
reports detail how patients at OTPs who receive their medication and leave the facility impaired, 
only to drive away and cause fatal motor vehicle accidents.334   
Research by public policy scholars Mary Wickersham and Stephanie Basey along with 
the sheer amount of media reports, lawsuits, and case law suggests the reported cases of patient 
injury, OTP clinic mismanagement, and harm to the public constitutes the tip of the iceberg to a 
much larger problem.  From 1996 to 2012, the number of OTPs doubled, and in June 2018 HHS 
announced the availability of $350 million in new funding to expand access to substance use 
                                                           
330 Sontag, supra note 269; Brandon Stahl, Methadone: ‘60s Treatment Comes With Deadly Risks Today, DULUTH 
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331 Stahl, supra note 330; SAMHSA Minimize Liability, supra note 213. 
332 See Benjamin Schachtman, Half of Wilmington’s Private Drug Treatment Facilities Cited, Including One for a 
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333 Swisher, supra note 281 (Swisher refers to the practice as “dose and go,” where the patient obtains the 
medication, but the OTP does not provide sufficient (or any) behavioral therapy to address the reasons for the 
underlying addiction).  See 42 C.F.R. § 8.12 (f). 
334 Nilsen, A Life Changer, supra note 42; Nilsen, A Stage Set, supra note 42; Kruger, supra note 42. 
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disorder and mental health services including MAT and OTPs.335  Expanding the current model 
for assuring the quality of OTPs translates to the potential for more patient exposure to facilities 
without effective oversight to their quality. 
B. Regulation of OTPs 
OTPs are regulated on both the federal and state level.336  Specific requirements set forth 
in 42 C.F.R. Part 8.12 designates that OTPs are required to be certified by SAMHSA and have a 
valid accreditation status; OTPs may be accredited by either the state or a private accreditation 
body, such as the Commission on Accreditation of Healthcare Facilities (CARF).337  According 
to SAMHSA, the regulations set forth minimum acceptable standards for the operation of OTPs, 
but are not intended as the professional standard of care.338  The regulations and corresponding 
guidance issued by SAMHSA outline details such as the appropriate administration and 
organization structure,339 quality assurance that includes the program’s goals and objectives for 
treatment,340 risk management and a system to report critical incidents (such as injuries or 
deaths),341 and a diversion control plan.342  Federal regulations also require a minimum amount 
of annual drug screening tests for patients enrolled in OTPs, but does not condition a patient’s 
continued enrollment or receipt of Controlled Substances with compliance.343  Instead, 
                                                           
335 HRSA Confronts Opioid Addiction, HEALTH RESOURCE AND SERVICES ADMINISTRATION (Sept. 21, 2017), 
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SAMHSA guidance warns against decreasing or limiting doses of maintenance medication in 
response to polysubstance abuse and instead suggests patient’s polysubstance abuse signals the 
need for more intensive counseling and an increased dose of maintenance medication.344 
Licensing requirements, reporting, and inspection practices within each state vary based 
on differing state law.345  Not all states require annual inspections, facilities may self-report 
partial metrics (such as number of enrolled patients and retention in treatment) but not metrics 
measuring polysubstance abuse and drug screen results, or impact of MAT on employment, 
criminal activity, or adverse health outcomes.346  Accordingly, measures of “success” may 
correspond to the number of enrolled patients, or the length of time in treatment without report of 
crucial outcomes such as how many patients continue to abuse illicit substances and their quality 
of life.347 
The problem, according to Wickersham and Basey, is that accreditation status has 
become a signifier of quality but lacks uniformity and transparency.348  Wickersham & Basey’s 
findings provide substantive research supporting troubling media stories349 reporting how state 
                                                           
344 Federal Guidelines for Opioid Treatment Programs, supra note 295, at 51-52 (asserting programs shall not adjust 
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health departments discovered OTPs with egregious compliance violations offering substandard 
patient care despite high marks from CARF.350  Further, some states do not require annual 
inspections, which means no accounting of violations may exist, or alternatively, the public may 
only discover violations after a legal complaint or publicized crime, such as patient death or 
motor vehicle fatality.351  
C. Impact on Patient Care and Public Safety 
 The gaps in regulation, compliance, and enforcement translates to discrepancies in 
provider quality, and creates a permissive regulatory environment for substandard medical care.  
This impacts not only the patient’s life and well-being, but also public safety if patients are 
impaired from prescribed medication, continue to engage in polysubstance abuse, and/or divert 
the medication they receive into the illicit market.352  Across the United States, patients who 
sought comprehensive treatment for addiction filed lawsuits against OTPs, alleging claims 
including negligence, medical malpractice, and fraud.353  Former patients assert the OTP 
                                                           
Treatment Center high marks); Duluth Methadone Clinic Cited for 22 New ‘Serious and Substantial Violations, 
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See, generally SAMHSA Effective Strategies, supra note 275; SAMHSA Risk Management, supra note 275; 
SAMHSA Minimize Liability, supra note 213. 
353 Plaintiffs’ Complaint, [Redacted Class Action Plaintiffs] v. Colonial Management Group et al. (M.D. Ala 2010), 
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provided failed to provide comprehensive counseling to address the social and psychological 
factors underlying their addiction and instead solely prescribed methadone, which resulted in 
serious physical and psychological adverse effects, fueling an addiction to another Controlled 
Substance.354  Patients who are enrolled in treatment at an OTP may also overdose and die,355 but 
polysubstance abuse may undermine the ability to determine causality (whether the death was 
caused solely or partially by the prescribed opioid), creating a high bar effectively precluding 
legal recourse.356  Despite reports of patient harm in media357 and several Plaintiffs 
complaints,358 there is a dearth of case law.359      
Case law across several jurisdictions has addressed patient impairment when the patient’s 
conduct impacts public safety and welfare.  In multiple cases, patients who attended an OTP to 
receive methadone continued to abuse other illicit substance while enrolled in MAT.360  Patients 
                                                           
methadone, and engaged in a plan to induce patient dependence on methadone); Plaintiff’s Complaint, Shawna 
Palmer v. Karl Lanocha and Metro Treatment of New Hampshire, (D.N.H. 2010) (Plaintiff alleged the OTP did not 
provide comprehensive addiction treatment services, but fostered Plaintiff’s addiction by merely providing a new 
Controlled Substance in the form of methadone) (on file with author courtesy of Abramson, Brown, and Dugan, 
PA); see also Plaintiff’s Complaint, Jenna Lydon v. Dennis Swartout and Metro Treatment of New Hampshire, 
(D.N.H. 2010) (where Plaintiff was a pedestrian victim of a motor vehicle accident by a patient of the named OTP 
and alleges the OTP failed to provide comprehensive addiction treatment services, but instead merely provided 
Controlled Substances to a patient who continued to engage in polysubstance abuse) (on file with author courtesy of 
Abramson, Brown, and Dugan, PA). 
354 Id.   
355 Piscitelli v. Hospital Authority of Valdosta, 691 S.E.2d 616 (11th Cir. 2010) (Deceased patient was enrolled in a 
drug and alcohol abuse treatment facility and died during the induction period four days into treatment and the 
medical examiner testified patient cause of death was methadone toxicity); see also SAMHSA Minimize Liability, 
supra note 213. 
356 Id.; but see Procaccini v. Lawrence and Memorial Hospital Inc., 168 A.3d 538 (Conn. App. Ct. 2017) (Deceased 
patient previously received treatment at an OTP wherein she received methadone.  The OTP discharged patient, and 
one week after patient’s last dose of prescribed methadone, the patient obtained illicit methadone and overdosed, 
dying of respiratory distress despite administration of naloxone and admission for emergency care.) 
357 See Swisher, supra note 281; Macy, supra note 285; Stahl, supra note 285; Sontag, supra note 41. 
358 See Wickersham & Basey, supra note 345.   
359 If patients are engaging in polysubstance abuse, this both convolutes potential causality, may constitute evidence 
of comparative negligence, and patients who are substance abusers generally may present with the stigma of being 
an unsympathetic plaintiff.  According to a phone conversation with attorney Richard Shapiro and email 
communications with attorney Holly Haines, the attorneys discussed with the author how settlements not only 
impact lack of case law, but decrease transparency and ability to track the extent of legal complaints against OTPs.  
360 Cheeks v. Dorsey, 846 So.2d 1169 (4th Cir. 2003); Taylor v. Smith, 892 So.2d 887 (Ala. 2004); Order, Lingren v. 
Pinnacle Recovery Services, No. 09-CV-13-215, No. 09-CV-14-760 (D. Minn. 2014)(on file with author). 
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may explicitly disclose their intention to continue to abuse multiple substances,361 they may 
demonstrate impairment (appearing disoriented, upset, red eyes, or nodding off),362 or may have 
physical signs of continued substance abuse (new intravenous marks).363 
  Many patients who visit an OTP drive extensive distances (over an hour) to attend the 
clinic, receive their medication, then drive to work or home.364  In Lingren v. Pinnacle Recovery 
Services, patient Vanessa Brigan arrived early at Pinnacle Recovery Services to receive her daily 
dose of methadone, “presented herself with fresh track marks, marijuana in her system, and 
nodding off in the waiting room prior to receiving her methadone dose.”  Pinnacle Recovery 
Services provided Brigan the same daily dose and provided her a “take home” dose, despite 
physical evidence she was injecting her take home doses while simultaneously abusing other 
illicit substances.365  Brigan drove away from the facility and stopped at a gas station to inject the 
“take home dose.”366  Driving impaired under the influence of marijuana and two doses of 
methadone, Brigan crossed the center line on the highway, striking another vehicle and killing 
the driver.367  If OTPs do not share metrics of continued opioid abuse, polysubstance abuse, or 
                                                           
361 Taylor v. Smith, 892 So.2d 887 (Ala. 2004). 
362 Cheeks v. Dorsey, 846 So.2d 1169, 1171 (4th Cir. 2003) (describing patient Reutlinger had red eyes and looked 
upset and disoriented “as if he had been doing cocaine or methamphetamines); Order, Lingren v. Pinnacle Recovery 
Services, No. 09-CV-13-215, No. 09-CV-14-760 (D. Minn. 2014) at 14 (patient Brigan was nodding off in the 
waiting room). 
363 Order, Lingren v. Pinnacle Recovery Services, No. 09-CV-13-215, No. 09-CV-14-760 (D. Minn. 2014) at 15 
(“Brigan presented herself to the clinic with fresh tacks marks on her arms, marijuana in her system, and nodding off 
in the waiting room prior to receiving her methadone doses”). 
364 Order, Lingren v. Pinnacle Recovery Services, No. 09-CV-13-215, No. 09-CV-14-760 (D. Minn. 2014) at 14 
(stating patient Brigan drove over 100 miles to and from the clinic each day); Taylor v. Smith, 892 So.2d 887, 891 
(Ala. 2004)(stating patient Ennis drove 90 minutes to and from the clinic each day).  Some patients may arrange 
alternative transportation or use a taxi.  See also Del Real, supra note 296. 
365 Amended Plaintiff’s Complaint, Lingren v. Pinnacle Recovery Services, No. 09-CV-13-215 (D. Minn. 2013) (on 
file with author) at 3 (stating Brigan “regularly and routinely injected her take-home doses of methadone 
intravenously,” and had evidence of the injections “visible on her skin”), at 4 (Brigan injected the methadone at a 
gas station), at 5 (toxicology tests showed THC and methadone present in Brigan’s system at the time of the motor 
vehicle accident). 
366 Id. 
367 Kruger, supra note 40. 
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track patient impairment, then it is foreseeable cases like Vanessa Brigan constitute only the tip 
of the iceberg. 
In similar cases such as Cheeks v. Dorsey, the court held OTPs have a duty to screen their 
patients and adopt a policy for how to address when patients present with impairment at the 
clinic.368  Without toxicology screening or an effective policy to monitor the patient, advise the 
patient against driving, or arrange for alternate transportation, the OTP creates a risk that 
unidentifiable third parties may become injured when the patient drives away from the clinic.369  
Some OTPs may have a drug screening policy in place and are acutely aware of patients’ 
ongoing abuse of multiple illicit substances because patients repeatedly test positive.370  Yet if 
the OTP adheres to SAMHSA’s guidance stating patient noncompliance should not prompt a 
decrease or limitation in their maintenance medication and the OTP continues providing 
maintenance medication to the patient, then the OTP likely faces liability if the patients leaves 
the clinic impaired and causes injury to others.371  
 
 
                                                           
368 Cheeks v. Dorsey, 846 So.2d 1169 at 1170, 1173 (4th Cir. 2003); see, generally SAMHSA Effective Strategies, 
supra note 275 (discussing patient impairment); SAMHSA Risk Management, supra note 275, at 25 (discussing 
multiple sources of impairment), at 26, 30 (describing foreseeable harm to third parties from patient impairment), at 
27 (discussing a duty to screen for patient impairment); SAMHSA Minimize Liability, supra note 213, at 17, 24 
(describing the pharmacokinetics of methadone as a central nervous system depressant that can build in tissue and 
cause impairment and death). 
369 Id. 
370 Taylor v. Smith, 892 So.2d 887, 888-889 (Ala. 2004). (Patient Ennis 13/14 urinalysis screens showed the 
presence of additional illicit substances in addition to methadone, including non-prescribed benzodiazepines and 
cannabis and patient reported “no desire to stop using.”  The OTP medical clinic director continued to provide daily 
doses of methadone to patient Ennis.)  But see Moore v. Western Carolina, 182 F.Supp.3d 825, 835-836 (E.D. Tenn. 
2016) (OTP may not have a duty to injured third parties if the methadone patient does not show signs of impairment 
even if methadone patient was in actuality impaired). 
371 Id.; Federal Guidelines for Opioid Treatment Providers, supra note 295, at 51-52 (asserting programs shall not 
adjust doses to reinforce positive behavior or punish negative behavior and positive toxicology screens may indicate 
the need for an increased dosage of maintenance medication), at 20 (describing the appropriate response of more 
intensive counseling to address polysubstance abuse). 
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D. The Impact of a Flawed Treatment Model 
This particular component of SAMHSA’s guidance constitutes a critical flaw, because it 
both glosses over the significance of the patient’s continued drug abuse – a signal that MAT is 
ineffective at addressing patient’s underlying addiction – and it places the public in harm’s way 
from the conduct of the impaired patient.  The effects of inadequate treatment impact the patient, 
who continues to suffer addiction and adverse health effects that preclude recovery and 
integration back to society.  Presuming patients enrolled in MAT will continue to abuse illicit 
substances and continuing to provide opioid agonist medications for patients to engage in self-
harm is neither compassionate nor ethical.  Such actions signal resignation to the patient, who 
will suffer ongoing physical and psychological despair.  In the cases describe above, patient 
impairment reverberates to society when patients drive away from the clinic and cause 
permanent and disabling injury to other motorists,372 motor vehicle fatalities,373 and crash into 
unsuspecting pedestrians.374  Patients also faces criminal charges with incarceration for injuries 
and deaths that cannot be undone simply because they were impaired.375  These outcomes 
compel a re-examination of how MAT impacts both patients and how supporting the expansion 
of MAT as a health policy strategy will magnify shortcomings of ineffective treatment and 
societal harm. 
CONCLUSION 
Julie Eldred represents only one face of persons with OUD as a patient with a history of 
addiction to opioids who became entangled in the criminal justice system from crimes she 
                                                           
372 Taylor v. Smith, 892 So.2d 887 (Ala. 2004). 
373 Cheeks v. Dorsey, 846 So.2d 1169 at 1170, 1173 (4th Cir. 2003); Order, Lingren v. Pinnacle Recovery Services, 
No. 09-CV-13-215, No. 09-CV-14-760 (D. Minn. 2014). 
374 Nilsen, supra note 42.  
375 Id.; Taylor v. Smith, 892 So.2d 887 (Ala. 2004); Cheeks v. Dorsey, 846 So.2d 1169 at 1170, 1173 (4th Cir. 2003); 
Order, Lingren v. Pinnacle Recovery Services, No. 09-CV-13-215, No. 09-CV-14-760 (D. Minn. 2014). 
  
66 
committed to fuel her addiction.  The amicus briefs filed in support of Eldred and rhetoric set 
forth by NIDA and SAMHSA portray a bleak prognosis for person suffering from addiction: 
Eldred suffers from a chronic, relapsing brain disease over which she has little control and 
enrolling her in MAT with a prescription for Suboxone constitutes the most effective form of 
treatment.  Yet extensive research in addiction science contradicts each of these statements, 
showing narrow neurobiological models may undermine recovery, hinder appropriate medical 
care that addresses polysubstance abuse, and confuse perceptions of legal culpability.  The 
current brain disease model of addiction constrains how we conceptualize addiction as a complex 
series of choices that may or may not require different levels of treatment to address the social 
and psychological issues underlying the patient’s addiction.   
Importantly, discussing OUD requires precision to separate persons with addiction who 
may require extensive supportive treatment from persons with physiological dependence 
attempting to discontinue prescribed medication but facing severe physical and psychological 
withdrawal symptoms.  Research on MAT demonstrates an extensive profile of physical risks 
that negatively impact quality of life; research demonstrating neurological damage from opioid 
agonist maintenance treatment and risks from opioid antagonist treatment; and forceful financial 
entanglements promoting pharmacological solutions.  Long term MAT for persons with 
iatrogenic opioid dependence is not only inappropriate, but as Fischer and colleagues suggested 
will likely create a new epidemic of impaired persons dependent or addicted to a new controlled 
substance. 
For persons who do suffer from addiction, available research casts doubt on the efficacy 
of MAT because the majority of patients continue polysubstance abuse, some may develop 
dependence or addiction to the prescribed maintenance medication itself, and patients may 
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continue to struggle with activities of daily life undermining claims of reintegration and 
recovery.  As OTPs expand, patterns from media reports, lawsuits, and case law suggest 
discrepancies in provider quality, portray numerous facilities as merely providing another opioid 
without providing comprehensive treatment, and demonstrate insufficient attention to addressing 
patients’ extensive medical, psychological, and social needs.  This model not only fails to as a 
policy for promoting compassionate and evidence-based care for persons struggling with 
addiction but places the public at risk of more crime and injury arising from patients’ 
maladaptive actions arising from impaired decision-making.   
 
 
 
